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1 Introduction 
 
1.1 Vascular gene therapy 
 
By definition, gene therapy is the delivery of recombinant nucleic acids to somatic host 
cells with the intention to modulate endogenous gene expression thereby achieving 
significant improvement or reduced progression of a disease. In addition, a successful gene 
therapy might yield long-term effects which may supersede the need of drugs or even 
surgical interventions. In general, three types of gene modifications can be distinguished: 
• Replacement of a mutated gene by its intact form, 
• Inactivation of ‘bad’ gene substantially involved in genesis or progression of a 
disease (knock out), 
• Introduction of a ‘good’ gene resulting in disease regression (knock in). 
However, the whole topic of gene therapy requires considerations which are much more 
complex than just knocking a gene out or in. Also temporal and spacial factors, such as 
stability and location of the transgene expression are important. Uncontrolled gene transfer 
to non-target cells might turn beneficial effects of a therapy into severe side effects and too 
low expression can make the whole intervention useless. Therefore, the development of 
new gene targeting strategies is an important prerequisite to make gene therapy indeed a 
standard procedure for clinical application. 
Effectivity and specificity of an implemented genetic modification strongly depend on the 
route of administration. The term intravascular gene therapy involves all types of 
therapeutic strategies where genetic vectors are applied via the systemic circulation. This 
form of application seems to be most reasonable for a variety of diseases involving the 
circulatory system such as cardiovascular diseases and a variety of solid tumors. However, 
vascular gene therapy remains challenging due to conditions given in the circulation, such 
as shear forces due to blood flow, systemic dilution and biological clearance mechanisms 
resulting from protein binding or immune cell activation 
1
. Altogether these factors are 
causative for a strongly reduced local amount and therefore ineffective quantities of the 
therapeutic substance at the desired site. In most cases, an increase of dose is not always a 
rational answer to this problem as this may result also in enhanced drug actions at 
unintended sites in the body thereby inducing severe systemic side effects. For that reason 
intravascular gene therapy is still at a disadvantage to other approaches, such as local tissue 
injection. However, great scientific efforts are put into the abolition of these disadvantages 
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to finally utilize the natural benefits given by the circulation for gene therapeutic targeting: 
• Passive convective transport of injected genetic vectors, 
• Close proximity to an intended area of treatment (e.g. vascular cells, organs etc.), 
• Low invasiveness of intravascular injection. 
The potential areas of application for vascular gene therapy are various including treatment 
of inherited disorders, cancer or diseases of the cardiovascular system. As such diseases 
oftentimes demand the treatment of a localized vascular compartment, gene targeting is 
desirable. In addition, the development of an effective vascular gene delivery method has a 
substantial value for experimental studies of certain genes and proteins in vivo.  
However, first clinical studies did not fulfill the initial promising expectations excited by 
prior animal studies 
2
. Humoral and cellular immune responses, inefficient gene targeting 
and too low transgene expression may account for this. Therefore, more effective and safer 
gene delivery strategies are highly demanded to establish vascular gene therapy as a 
general procedure of clinical therapy. 
 
 
1.2 Viral vectors applied in vascular gene therapy 
 
The hydrophobic membranes of mammalian cells represent effective barriers against the 
introduction of naked genetic material (e.g. DNA and RNA). Therefore, successful gene 
therapy using these vectors has oftentimes proven challenging 
3
. To overcome this basic 
natural hurdle, different physical (e.g. electroporation, sonication), chemical (e.g. 
lipofection, polymers) or biological (e.g. viral vectors) tools have been developed and are 
applied by scientists, either alone or in combination 
1
. 
In this regard, especially viruses moved into the centre of attention of scientific efforts. 
Due to their unique evolutionary strategy to conquer the host cell´s membrane via active or 
passive mechanisms, viral vectors represent perfectly suitable vehicles for gene therapy 
2, 4
. 
Accordingly, many experimental and clinical studies already applied virus-mediated gene 
delivery in order to achieve therapeutic gene expression. Importantly, to increase safety of 
virus-mediated gene therapy in patients, recombination technologies to modify the viral 
genome have been implemented resulting in more secure second- and third-generation 
virions 
5
. There, viral genes encoding components dispensable for infection (e.g. 
replication proteins) have been removed resulting in replication deficient viruses capable to 
infect host cells only once. Among the available viruses, adenoviruses, adeno-associated 
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viruses and lentiviruses have been used most frequently in experimental and clinical gene 
therapy studies 
6, 7
. Due to their considerable differences regarding genome structure, way 
of infection and transgene expression, the choice of an adequate vector needs to be 
considered carefully depending on the respective aspired therapeutic aim. 
Adenoviruses are non-enveloped dsDNA viruses and infect dividing and non-dividing cells 
mainly via endosomal entry 
2
. As they do not integrate into the host genome, adenoviruses 
are not associated with a known risk of insertional mutagenesis or genotoxicity. However, 
strong activation of the innate immune system results in profound limitations. Furthermore, 
the extrachromosomal state of the viral genome and the resulting transient transgene 
expression (< 14 days 
8
) excludes adenoviruses for long-term gene therapeutic 
applications. 
Adeno-associated viruses (AAV) from the family of Parvoviridae are non-enveloped 
ssDNA viruses, which attracted considerable interest for gene therapy due to their non-
pathogenicity and low immunogenicity in vivo 
2, 9
. Similar to adenoviruses, they infect 
dividing as well as non-dividing cells resulting in an extrachromosomal existence. Gene 
expression has been shown to persist longer (3-12 month 
8, 10
) compared to adenovirus-
mediated transduction, however, still remains transient. So far 13 AAV serotypes are 
known, whereby some of them show promising cellular tropisms (e.g. cardiotropic AAV9 
or hepatotrophic AAV5) advantageous for organ specific expression upon systemic 
application. Unfortunately a considerable prevalence of patients with pre-existing 
neutralizing antibodies restricts the use of these vectors for clinical application 
11
. 
Lentiviruses from the Retroviridae family contain a ssRNA genome and have been 
advanced from the human immunodeficiency virus-1 (HIV-1) 
12, 13
. The current third-
generation lentiviruses contain no more than 3 of the former 9 HIV-1 genes (named gag, 
pol and env), making them safe vectors applicable for in vivo gene transfer 
5
. They infect 
dividing and non-dividing cells whereby their infection spectrum was significantly 
enhanced by recombinant replacement of the original envelope protein (env) by a VSV-G 
envelope protein (derived from vesicular stomatitis virus). The undeniable advantage of 
lentiviruses for gene delivery over other virus types persists in their ability to integrate 
their own genome cDNA into the host’s genome resulting in stable and heritable transgene 
expression. A detailed scheme of the lentivirus structure and infection mechanism is 
depicted in Figure 1.1. Importantly, it has been shown that the integration of the lentiviral 
genome is predominantly occurring in downstream gene regions rather than promotor 
regions thereby significantly decreasing the risk of genotoxicity 
7
. However, the former 
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mentioned broad infection spectrum of lentiviruses also represents a drawback especially 
for their therapeutic application via the circulatory system. Without a supportive targeting 
and shielding system, lentiviruses become rapidly cleared by circulating immune cells as 
well as infect cells at unintended sites leading to severe side effects. Accordingly, no 
clinical studies using lentivirus-mediated intravascular gene delivery have been performed 
so far. However, the general benefit of lentiviruses as therapeutic vehicles for gene therapy 
has been proven in clinical studies facilitating ex vivo transduction of autologous 
hematopoietic stem cells following cell transplantation in patients with β-thalassemia 
14
, X-
linked adrenoleukodystrophy (ALD) 
15
 and Wiskott–Aldrich syndrome (WAS) 
16
. The 
beneficial outcomes achieved in these patients strongly support the prospect that 
lentiviruses may be the first-choice gene vehicles for long-term gene therapy in the near 
future. Therefore, the development of carrier approaches enabling targeted delivery and 
reduced unspecific transduction by lentiviruses in vivo is an important step to take. 
 
 
Figure 1.1. Lentivirus structure and infection/replication cycle. 
(a) Unmodified lentiviruses feature an enveloped capsid core containing two copies of ssRNA as 
well as integrase, reverse transcriptase and proteases. (b) The natural infection and replication 
cycle of lentiviruses is shown. Recombinant lentiviral particles applied in gene therapy are 
deficient in viral replication and propagation. Adapted and modified from Eric P. O’Keefe, 
MATER METHODS 2013;3:174.  
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1.3 Available carrier systems for improved and guidable gene therapy 
 
Low gene transfer and targeting efficiency are still the major obstacles limiting successful 
vascular gene therapy. To overcome these, supportive gene delivery systems capable of 
improving circulation time and drug targeting are needed. In this regard, important 
prerequisites such as non-toxicity, non-immunogenicity and biodegradability have to be 
considered before a carrier is eligible for in vivo and even clinical application. 
Furthermore, the binding behaviour between carrier and genetic vector must be effective 
and controllable. Thus, the binding stability between carrier and vector is as important as 
the triggered dissociation of both at the intended site of action. The implementation of 
surface modifications (charge, hydrophobicity, etc.) can substantially determine stability, 
binding behaviour and circulation time of the carrier and the bound therapeutic payload 
1
. 
Also, other factors such as size and rigidity may have considerable influence on the 
effectivity of an intravascularly applied vector-carrier-system. 
The range of available carriers, though, is as broad as the variety of genetic vectors. 
However, two categories have shown promising results in experimental studies and can 
therefore be highlighted: lipid- and nanoparticle-based gene carrier systems 
1, 17
. In the 
context of gene therapy, lipid-based ultrasonic microbubbles and magnetic nanoparticles 
have been shown to be capable of binding genetic vectors and support gene transfer in 
vitro and in vivo 
18, 19
. However, although both nanocarriers have been demonstrated to 
achieve targeted gene transfer upon either local ultrasound application (microbubbles) or 
magnetic field exposure (magnetic nanoparticles), they are still a far cry from standard 
procedures for clinical gene therapy. One possibility to maximize effectivity may be 
achieved by generating a synergistic carrier system combining the two mentioned 
approaches. The following sections will describe the single targeting methods in more 
detail and discuss the option of a combined approach. 
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1.3.1 Ultrasonic microbubbles – More than just contrast agents 
 
Microbubbles have already been applied as a contrast agent in diagnostic ultrasound 
imaging since three decades 
20
. Their additional potential as intravascular delivery vectors 
for biomaterials due to their unique physico-chemical properties was recognized around 15 
years ago 
18, 21
. In general, microbubbles can be generated from lipids, polymers or 
proteins, such as albumin, resulting in structures with very different physico-chemical 
properties 
22
. All three of them have been shown to be capable to bind and deliver genetic 
vectors at a desired vascular site upon local application of ultrasound 
22
. However, 
especially their excellent shell flexibility compared to the rather rigid polymer-based 
microbubbles as well as their high storage and circulation half life compared to protein-
based microbubbles makes the lipid microbubbles splendid nanocarriers for vascular 
applications 
22, 23
. Furthermore, lipid microbubbles are easily generated compared to other 
microbubble formulations as the amphiphilic lipids tend to self-assemble into small 
bubbles with diameters in the micrometer range around a gas-filled core, whereby the 
hydrophobic tails face the gas phase and interact via hydrophobic forces 
23
. The gas core is 
thereby oftentimes filled with a poorly water-soluble gas, such as perfluorocarbon gas, 
increasing the stability and half-life of the microbubbles. The already mentioned high 
shape flexibility of lipid microbubbles enables the passage through even the smallest blood 
vessels (capillaries) after intravascular application. Importantly, it has been shown that 
microbubbles efficiently bind genetic material, such as DNA, RNA, siRNA and viral 
vectors, and that this binding results in reduced systemic clearance and subsequent increase 
in bioavailability also designated as shielding 
23, 24
. By application of an acoustic pulse 
(ultrasound, US), the highly compressible microbubbles expand and contract. Depending 
on the strength of the applied US, this oscillation can be increased up to a frequency where 
the microbubble structure bursts. For the purpose of drug and gene targeting this disruption 
of microbubbles is highly desired, as it allows for controlled and localized substance 
release at the site of sonication. In addition, microbubble sonication has been shown to 
result in enhanced cellular uptake of the bound vectors due to temporal induction of 
cellular pores and intercellular cavities, a process called sonoporation 
25
. Although a 
certain site-specificity of gene transfer can be achieved by locally applied ultrasound, 
systemic dilution strongly hampers the benefits given by this approach. As only a minor 
fraction of microbubbles are abundant at the site of ultrasound application after systemic 
injection, a higher dose is required to achieve sufficient vector concentrations at the desired 
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tissue location and therefore efficient gene transfer to cells and tissues. In addition, longer 
sonication times, to enable disruption of a higher fraction of microbubbles, may cause 
unintended tissue damage and vessel leakage. Therefore, targeting mechanisms, 
supplemental to localized ultrasound application are under intense investigations 
1, 26
. 
 
 
1.3.2 Magnetic nanoparticle mediated gene targeting 
 
Magnetic nanoparticles (MNP) are nanomaterials excellently qualified for biomedical 
applications, such as magnetic resonance imaging 
27
, tumour hyperthermia 
28
 and drug 
targeting 
19
. The basic principle of directing and accumulating drug-loaded MNP by local 
application of an external magnetic field raised a huge scientific interest. In most 
experimental studies, MNP containing an iron-oxide core (also designated as 
superparamagnetic iron oxide nanoparticles; SPIONS) are used. In detail, iron-oxide MNP 
feature a γ-Fe2O3 (maghemite) or a Fe3O4 (magnetite) core resulting in intrinsic magnetism 
19
. Magnetisation of the particles is exclusively induced by application of an external 
magnetic field with no remaining magnetic interaction upon removal of the magnetic field. 
Improved chemical and biological behaviour of iron-oxide MNP can be achieved by their 
coating with organic and inorganic materials such as PEG (polyethylene glycol), PEI 
(polyethylenimine) or silica. Such surface functionalizations can influence the colloidal 
stability and storage life, but have also substantial impact on drug binding capacity, 
biocompatibility and performance in complex biological environments such as blood 
19
. 
Due to their small size they are able to pass cellular membranes whereby they potentially 
increase the cellular uptake of the bound substance by dragging it along. Concerning 
biocompatibility aspects, iron-oxide MNP have mostly been found to possess low 
cytotoxicity in vitro and in vivo. Especially if applied in low concentrations of <100 µg/ml 
relatively good compatibility and safety has been attested even in humans 
29, 30
. Long-term, 
iron-oxide MNP are suggested to be mainly eliminated from the body via the hepatic iron 
metabolism resulting either in uptake to endogenous iron stores or renal excretion 
31
. MNP-
assisted gene transfer, so called magnetofection, is already an established approach 
alternatively applied to common in vitro transfection methods such as lipofection 
32-34
. In 
several studies, MNP coated with viral 
35, 36
 and non-viral vectors 
32, 37
 have been tested for 
magnetically directed in vivo gene transfer. However, extensive interactions of MNP with 
blood cells, plasma proteins and glycocalix observed after systemic injection dampened the 
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initial hope of an easy guidable gene carrier system for vascular therapy 
19, 27
. Therefore, 
the development of MNP with improved circulation time, magnetic susceptibility and 
vector coupling is still ongoing and also paved the way to combined approaches, such as 
magnetic nanocapsules, liposomes and microbubbles 
19
. These, however, still need to be 
evaluated for their compatibility and effectivity in vivo. 
 
 
1.3.3 Magnetic microbubbles – Combining shielding with targeting 
 
The functionalization of microbubbles by coating them with different nanomaterials is a 
highly active field of research at the moment. Especially the embedding of 
superparamagnetic iron-oxide nanoparticles within the lipid monolayer represents a 
promising advancement in this regard. In the area of multi-modal imaging, such magnetic 
microbubbles (MMB) have been successfully tested for simultaneous magnetic resonance 
and ultrasound imaging after intravenous injection in vivo 
38, 39
. Besides, the combination 
of ultrasound sensitive microbubbles, known for their good circulation behaviour, with 
magnetic nanoparticles, excellently suited for magnetic guidance and attraction even under 
flow conditions, may yield a synergistic gene delivery system with outstanding efficiency. 
MMB as nanocarriers for therapeutic genes have been addressed by some studies aiming at 
localized magnetic accumulation and, in some cases, their controlled ultrasonic burst 
38, 40-
42
. In general the MMB targeting procedures applied in these studies comprised the 
following components and parameters: 
• Microbubbles generated from lipid solutions 
• Magnetic nanoparticles for microbubble coating 
• An external magnetic field gradient for accumulation of MMB 
• Ultrasound for MMB rupture and release of payload 
• Therapeutic payload (drug or genetic vector) 
Due to the complexity of this targeting approach and the different in vitro, ex vivo and in 
vivo models used in the different studies, a direct comparison is hard to accomplish. 
However, only one study conducted in our group verified the functionality of MMB as 
guidable gene carrier system in vivo 
40
. There, localized vascular targeting of MMB-
coupled pDNA encoding a dsRed protein was successfully accomplished by application of 
a magnetic field and ultrasound. With the prospect to enhance vascular gene delivery, the 
applied MMB, prepared from a home-made phosholipid solution containing PEI-coated 
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MNP (Figure 1.2), has furthermore been used to generate lentiviral magnetic microbubbles 
in a second study 
41
. Promising transduction rates have been achieved with these lentiviral 
PEI-Mag MMB in vitro, however their performance under complex in vivo conditions still 
has to be assessed. Furthermore, the constant progress of MNP development requires the 
regular re-evaluation of MMB-based gene carriers and their comparison to alternative 
compositions. 
 
 
 
Figure 1.2. Self-assembly of magnetic microbubbles. 
(a) and (b) Rapid shaking of a perfluorocarbon gas coated lipid-MNP mixture induces self-
assembly of MNP-coated microbubbles (magnetic microbubbles, MMB) floating to the surface.   
(c) Microscopic image of MMB in solution. (d) Schematic illustration of a MMB featuring a gas-
filled core and a phospholipid monolayer with incorporated MNP. Figure modified after Mannell et 
al. 
40
. 
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1.4 Targeting endothelial signaling by vascular gene therapy 
 
The vascular system is the central organ of supply (e.g. oxygen and nutrients), elimination 
(e.g. CO2 and metabolic end products) and regulation (e.g. hemostasis, immune responses 
and body temperature) taking part in essentially all processes of physiology. However, it is 
also involved in the development and progression of a variety of diseases and is therefore 
central object of scientific and clinical therapy. Endothelial cells are of huge interest in this 
regard. Due to their easy access from the blood and general importance for tissue 
homeostasis, endothelial cells are attractive targets for purposes regarding the therapeutic 
modulation of angiogenic, inflammatory or thrombotic processes. 
 
 
1.4.1 The physiology and patho-physiology of vascular endothelium 
 
The vascular endothelium, a single layer of endothelial cells sitting on a basal lamina, 
constitutes the inner lining of all blood vessels and therefore represents the barrier between 
blood and tissue. Endothelial cells are responsible for the regulation of a multitude of 
physiological functions regarding the circulatory system, including regulation of material 
transport and cell transit, adjustment of the vascular tone and maintenance of hemostasis 
43
. 
The balance of these processes is finely adjusted by signaling processes responding to 
stimuli such as growth factors, cytokines and hormones, changes in shear stress or 
interactions with blood cells 
44
. Under physiological circumstances, these signaling 
processes ensure an anti-thrombotic, vasodilative and anti-inflammatory state of the 
endothelium. However, considering this fundamentally important role of endothelial cells 
for the functioning of the circulatory system, it is not surprising that their dysfunction has 
been shown to be causative for a variety of diseases, such as peripheral vascular disease, 
stroke and venous thrombosis 
43, 44
. In general, endothelial dysfunction can be defined as a 
pathological condition where the endothelium features pro-thrombotic, vasoconstrictive 
and/or pro-inflammatory properties. 
A prevalent clinical condition, which has become interesting in the context of endothelial 
dysfunction, is insulin resistance, a pathological state in which the regular cellular response 
to insulin fails 
45, 46
. Chronic insulin resistance may arise from permanent exposure of 
insulin responsive cells to abnormally high blood levels of insulin and glucose as can be 
found in pre-diabetic or obese patients. Untreated this condition may result in the full 
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manifestation of diabetes mellitus or metabolic syndrome. The result is a disturbed glucose 
homeostasis affecting the skeletal muscle, adipose tissue and liver. Furthermore, it has 
been shown that the incapacity of endothelial cells to respond to insulin leads to their 
dysfunction and is associated with deregulation of microcirculatory responses. Hence, 
these patients not only suffer from deregulated glucose metabolism but also develop severe 
secondary cardiovascular complications such as venous thrombosis, myocardial infarction, 
stroke and atherosclerosis 
46, 47
. Furthermore, a large portion of patients featuring insulin 
resistance exhibit an impaired wound healing capacity 
48, 49
. Explanations for this were 
found in a disturbed molecular equilibrium resulting in reduced production of 
vasoprotective substances (NO, prostacyclin) and over production of pro-inflammatory and 
–thrombotic factors (ROS, adhesion molecules, endothelin-1). The detailed disclosure of 
the molecular players involved in the development of endothelial dysfunction is the 
essential basis for the identification and application of new therapeutic targets. 
A further, likewise important function in which endothelial cells are essentially engaged is 
angiogenesis, a process involving the induced proliferation and migration of endothelial 
cells from pre-existing vessels fundamentally important for the generation of any mature 
vessel 
50
. The proper functioning of these processes is essential not only during embryonic 
development but also during adulthood e.g. for wound-healing. However, the 
malfunctioning of these angiogenic processes can lead to severe pathological conditions 
associated with either hyper- or hypovascularization, such as tumor growth or ischemic 
diseases, respectively 
51, 52
. The therapeutic aim to treat these diseases by modulating 
angiogenic processes requires careful and ideally local treatment approaches. 
Several therapeutic strategies, including genetic approaches, aiming for the beneficial re-
equilibration of endothelial function are intensively explored and partially applied already. 
The therapeutic delivery of genes provides the opportunity to re-equilibrate disturbed 
intracellular processes thereby attenuating symptoms and progression of a disease. In 
addition, expression-based modulation of endothelial function may achieve efficient long-
term effects, which might be otherwise only realized by constant drug application. 
Furthermore, experimental gene targeting in vivo may help to elucidate gene and protein 
functions involved in endothelial patho-physiological processes. The ability to locally 
modulate the endothelial gene expression within a desired organ or tissue might be a 
powerful tool to answer complex scientific questions superseding the complicated and time 
consuming process of generating conditional transgenic animals. 
The choice of putative targets for experimental and clinical endothelial gene therapy is 
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huge, especially as scientific research gains increasingly detailed information about the 
molecular basis of diseases. In the following two sections the focus is laid on two 
promising molecules which are interesting candidates being addressed as therapeutic or 
scientific targets to be studied by help of gene delivery approaches, such as the new 
lentiviral MMB technique. 
 
 
1.4.2 The vascular endothelial growth factor as target for therapeutic angiogenesis 
 
The vascular endothelial growth factor (VEGF) is a highly potent angiogenic factor with 
unique actions on vascular endothelium. Its secretion and recognition is crucial to initiate 
the formation of immature vessels by vasculogenesis or angiogenic sprouting 
53
. Besides 
its important physiological role during embryonic development and wound healing, it is 
also involved during several patho-physiological conditions, such as ischemia, diabetic 
retinopathy and tumour vascularization 
53
. Hence, VEGF has been used as a therapeutic 
target either to promote vascularization by its induction 
54, 55
 or to impair vessel growth by 
its inhibition 
56
. In experimental studies aiming at the revascularization of ischemic tissues 
(e.g. hindlimb-ischemia in rabbit 
57
 or myocardial ischemia in pigs 
58
) VEGF expression 
has been shown to result in long-term benefits. Accordingly, VEGF-mediated therapeutic 
angiogenesis by gene therapeutic approaches has been attempted in a variety of clinical 
phase I/II studies. There, pDNA 
59-61
 or adenoviral vectors 
62, 63
 have been used in patients 
with coronary heart disease or peripheral arterial disease whereby successful vector 
delivery was only achieved by direct tissue injection or local catheter-application of the 
genetic vectors 
55, 64, 65
. Unfortunately, in most of these studies VEGF expression yielded 
only unsatisfactory patient outcomes and therefore did not reflect the beneficial effects 
seen in the animal studies 
65
. Too low gene transfer efficiencies and accordingly 
insufficient VEGF expression might be the chief cause for these negative results. 
Therefore, an advanced intravascular targeting strategy may constitute a valuable tool to 
achieve effective localized modulation of angiogenesis by targeted gene delivery of VEGF 
via the circulation. 
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1.4.3 The protein-tyrosine phosphatase SHP-2 in endothelial dysfunction 
 
The SH2 domain-containing protein tyrosine phosphatase-2 (SHP-2; synonyms: SH-PTP2, 
SH-PTP3, PT-P2C, PTP1D or Syp) is a cytosolic phosphatase ubiquitously expressed in 
virtually all types of mammalian cells 
66
. On the structural level, SHP-2 possesses three 
functional domains: two N-terminal SH2 domains, a central catalytic phosphatase domain 
and two C-terminals tyrosine phosphorylation sites (Tyr
542
 and Tyr
580
). Under basal 
conditions, SHP-2 is supposed to exist mainly in its auto-inhibited state as depicted in 
Figure 1.3. Upon cytokine or growth factor stimulation this inactive conformation is 
released rendering SHP-2 into a fully active enzyme or adaptor molecule 
66
. Depending on 
the involved functional domain, SHP-2 has been shown to participate in a variety of 
intracellular signaling cascades including the Ras/MAPK and the PI3K/AKT pathways 
66, 
67
 resulting in modulation of metabolic 
68, 69
, inflammatory 
66, 70-72
 and motogenic responses 
73-75
. In endothelial cells, SHP-2 has been identified as an important regulator of 
angiogenic 
75, 76
 and inflammatory processes 
72, 77, 78
. The development of endothelial 
dysfunction induced under chronically high insulin levels, as observed in the condition of 
insulin resistance or diabetes mellitus, has been shown to be substantially influenced by 
SHP-2’s enzyme activity as well as by its function as an adaptor molecule 
68, 69, 72
. 
However, the molecular mechanisms stated in these studies are partially inconsistent. To 
allow for a detailed elucidation of SHP-2-mediated processes during insulin resistance 
further detailed studies are necessary. The lentiviral MMB technique provides the 
opportunity to study SHP-2’s function in endothelial cells in vivo and may potentially help 
to verify SHP-2 as an attractive target for vascular therapy. 
 
 
 
 
Figure 1.3. Structure and signaling 
(A) SHP-2 features three functional domains, namely the two N
domain and two C-terminal tyrosine motifs
believed to exert rather low basal activity due to 
close association of the N-SH2 and the PTP domain. 
released upon binding of SHP
Signals can be conducted via further recruitment of SH2 domain containing binding partners to 
phosphorylated tyrosine residues of SHP
(E) A further model suggests a self
the interaction of the SH2 domains with the phosphorylated tyrosines.
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1.5 Aim of the thesis and study objective 
 
Endothelial dysfunction provides a substantial foundation for the development and 
progression of many cardiovascular diseases. Related therapeutic strategies oftentimes 
imply invasive interventions or repeated systemic drug applications known to result in 
side-effects due to unspecific drug uptake. For most cardiovascular pathologies, however, a 
local and long-lasting therapeutic strategy would be desirable. Furthermore, such an 
approach would represent an invaluable tool for experimental studies.  
The use of MMB for the delivery of genetic vectors from the systemic circulation to a 
desired site of the vasculature has shown promising results in experimental studies 
40, 41
. 
However, due to the rapid progress in the field of nanoparticle design, the MMB technique 
requires constant advancement and re-evaluation to provide maximal efficiency. Therefore 
the aim of this study was to answer the following questions: 
 
• Can a new type of silicon-oxide coated MNP (SO-Mag MNP) be used to generate 
lentiviral MMB? 
• Which physico-chemical (size, magnetic moment) and biological (lentivirus binding, 
cytotoxicity) properties do these new SO-Mag MMB possess and what are the 
differences compared to the formerly established PEI-Mag MMB? 
• Does magnetic and ultrasonic targeting of SO-Mag MMB to cultured endothelial cells 
yield an improved gene delivery efficiency compared to the PEI-Mag MMB? 
• How do the single technical parameters MMB, MF and US contribute to the enhanced 
gene transfer achieved by the lentiviral MMB technique and which cellular uptake 
mechanism is facilitated by MMB-mediated gene transfer? 
• Does the lentiviral MMB technique also enable local transduction of the intact 
endothelial layer in isolated mouse aortas? Can physiologically relevant effects be 
achieved in these vessels by the MMB-mediated introduction of a therapeutic gene, 
such as VEGF? 
• Which role does the protein tyrosine phosphatase SHP-2 play during endothelial 
insulin resistance and can these findings be translated to the ex vivo aorta model by 
using MMB-mediated gene transfer of SHP-2 mutant constructs? 
• Does the magnetic and ultrasonic targeting of systemically applied lentiviral SO-Mag 
MMB result in localized gene expression in vivo? 
• How do the applied MNP distribute in the body in short-term and what is the systemic 
expression pattern of the lentiviral vector? 
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2 Material and Methods 
 
2.1 In vitro and ex vivo studies 
 
2.1.1 Generation and production of lentiviral constructs 
 
Plasmids encoding SHP-2 wild type (WT) and the dominant negative mutant SHP-2 CS 
(Cys459 to Ser459) were a kind gift from Prof. Anton M. Bennett 
79
. A c-Myc-Tag 
sequence joined to the SHP-2 cDNA sequence allowed for distinction between 
endogenously and ectopically expressed SHP-2 and selective immunoprecipitation using a 
Myc-Tag antibody. The constitutively active mutant SHP-2 E76A (Glu76 to Ala76) was 
generated from SHP-2 WT using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent, CA, USA) following the manufacturer’s instructions. The SHP-2 constructs as 
well as constructs encoding human VEGF165, GFP and viral-enhanced firefly luciferase 
(veffLuc) were each subcloned into a self-inactivating RRL-lentiviral backbone under 
control of a CMV-promotor. SHP-2 constructs additionally contained an IRES-GFP co-
expression cassette allowing for detection of positively transduced cells. Non integrating 
fluorescence-labeled rrl-CMV-pCHIV.eGFP lentiviral particles were generated as 
described by Lampe et al. 
80
. Lentiviruses containing the different expression constructs 
were produced in cooperation with the viral vector platform of Prof. Alexander Pfeifer’s 
group (Bonn University) within the DFG Research Unit FOR917 
81
. Depending on the 
respective lentiviral construct, either the biological titer or the physical titer of the viral 
preparations was determined. For lentiviruses including a GFP-reporter cassette (GFP LV 
and SHP-2 WT/CS/E76A LV), biological titers (infectious particles (IP)/µl), were assessed 
by application to HEK293T cells following quantification of positively transduced cells by 
flow cytometry 
82
. For veffLuc LV, VEGF LV and pCHIV.eGFP LV the physical titer 
(viral particles (VP)/µl) was assessed by measuring the reverse transcriptase activity 
82
. 
 
Table 2.1. List of applied lentiviral vectors. 
Lentivirus Abbreviation Expression 
rrl-CMV-SHP-2 WT/CS/E76A-IRES-GFP SHP-2 WT/CS/E76A LV 
Myc-tagged SHP-2 proteins, 
GFP co-expression 
rrl-CMV-eGFP GFP LV GFP 
rrl-CMV-veffLuc veffLuc LV Firefly luciferase 
rrl-CMV-pCHIV.eGFP pCHIV.eGFP LV --- 
rrl-CMV-VEGF165(hu) VEGF LV Human VEGF165 
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2.1.2 Isolation and cultivation of human umbilical cord endothelial cells (HUVEC) 
 
All procedures involving primary endothelial cells were performed in accordance with the 
Declaration of Helsinki. Human umbilical cord endothelial cells (HUVEC) were isolated 
from the veins of human umbilical cords received from a local hospital. For storage, 
umbilical cords were placed in screw beakers (Sarstedt, Nümbrecht, Germany) with PBS+ 
supplemented with 1% penicillin/streptomycin (Sigma-Aldrich, Seelze, Germany). 
Isolation of HUVEC was performed at the latest 48 h upon receipt. Therefore, a buttoned 
cannula was inserted in one end of the vein and fixed with zip tie. The vein was perfused 
with 10 ml PBS- to wash out residual blood and a second buttoned cannula was inserted 
and fixed to the other side of the vein. Three-way-valves (Braun, Melsungen, Germany) 
were attached to the cannulas on both sides thereby allowing for filling of the vein with 5 
mg/ml Collagenase A solution (Roche, Basel Switzerland). The umbilical cord was placed 
in a pre-warmed waterbath (Memmert, Schwabach, Germany) at 37°C and incubated for 
10 min. Detached endothelial cells were rinsed from the vessel with 10 ml DMEM (Sigma-
Aldrich) and collected in a Falcon tube (Sarstedt) following centrifugation at 300 g for 5 
min. Pelleted cells were resuspended in 4 ml Endopan3 medium (PAN-Biotech, 
Aidenbach, Germany) and transferred to a T25 tissue culture flask (Sarstedt). HUVEC 
were cultured in a humidified incubator (Heraeus HERAcell, ThermoFischer Scientific, 
Waltham, USA) under 37°C and 5% CO2 conditions. Remaining blood cells were removed 
the following day by washing once with PBS+ and Endopan3 medium was exchanged 
daily until cells reached confluence. HUVEC were then transferred to 10 cm culture dishes 
(Sarstedt) and were further cultured with a 50/50 mixture of DMEM containing 20% FCS 
(Biochrom, Darmstadt, Germany) and Endopan3 supplemented with 1% 
penicillin/streptomycin (further referred to as HUVEC growth medium). For seeding, cells 
were washed with PBS- and detached by adding 1x trypsin/EDTA solution (Sigma-
Aldrich) for 2-3 min. Detached cells were subsequently resuspended in fresh HUVEC 
growth medium and transferred to appropriate dishes. All experiments with HUVEC were 
performed up to passage 5. 
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→ PBS + (Phosphate buffered saline with calcium and magnesium) 
136.9 mM NaCl 
2.7 mM KCl 
10.1 mM Na2HPO4 
1.8 mM KH2PO4 
0.42mM MgCl2 
4.5 mM CaCl2 
PBS+ was prepared in distilled water, brought to pH 7.4 and sterilized by filtration. 
 
→ PBS- (Phosphate buffered saline without calcium and magnesium) 
136.9 mM NaCl 
2.7 mM KCl 
10.1 mM Na2HPO4 
1.8 mM KH2PO4 
PBS- was prepared in distilled water, brought to pH 7.4 and sterilized by autoclaving. 
 
 
 
2.1.3 Freezing and thawing of HUVEC 
 
For long-term storage, cells from confluent 10 cm cell culture dishes were detached by 
adding 1x trypsin/EDTA solution and resuspended in 1 ml FCS supplemented with 10% 
DMSO (Sigma-Aldrich). Freezings were done in cryovials (Sarstedt) and gentle reduction 
of temperature (~1°C per minute) was achieved by using polystyrene containers (CoolCell, 
Biocision, San Rafael, USA). Cells were placed for 2 days in the -80°C freezer and were 
subsequently stored in liquid nitrogen. For restoration of cells into cell culture, the 
freezings were thawed quickly and added to 10 ml HUVEC growth medium in a 10 cm cell 
culture dish. Medium was exchanged after 4 h and cultivation was continued as described 
before. 
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2.1.4 Lentiviral transduction of HUVEC with SHP-2 mutants 
 
Over-expression of the SHP-2 WT and its functional mutants SHP-2 CS and E76A (all 
featuring a c-Myc-Tag) in HUVEC was achieved by lentiviral transduction with SHP-2 
WT/CS/E76A LV. In detail, IP corresponding to a multiplicity of infection (MOI) of 5 
were diluted in Hank’s balanced salt solution (HBSS; Biochrom, Berlin, Germany) and 
lentivirus solutions were applied onto subconfluent (~80%) cell cultures. After incubation 
for 4 h HUVEC growth medium was added and fresh medium was applied the next day. 
Cells were left 72 h for gene expression before assaying. 
 
 
 
2.1.5 Analysis of adhesion molecule surface expression by flow cytometry 
 
HUVEC grown in 6-well plates (Sarstedt) were treated with DMEM containing 15 mM 
glucose and 100 nM human insulin (Insuman Rapid 40 IU/ml, Sanofi Frankfurt a. Main, 
Germany) for 24 h and 48 h. To ensure proper bioactivity of insulin, stimulation medium 
on 48 h stimulated cells was refreshed after 24 h. To detect ICAM-1 and VCAM-1 surface 
expression, HUVEC were washed with PBS- and detached by Accutase (GE Healthcare, 
Solingen, Germany). Cells were then pelleted (1200 g, min), rinsed and incubated with 
allophycocyanin- (APC) labelled ICAM-1 and VCAM-1 antibodies (1:40 in PBS+; BD 
Bioscience, Heidelberg, Germany) for 30 min at room temperature in the dark. Cells were 
washed, resuspended in 250 µl PBS+ and transferred to FACS tubes (Sarstedt). APC-
fluorescence intensities were detected by flow cytometry using a FACS Canto II (BD 
Bioscience). Alongside, cells incubated with an APC-labelled IgG1 isotype antibody were 
measured as control for unspecific antibody binding. Cells positively transduced with the 
SHP-2-WT/CS/E76A LV were identified by detection of co-expressed GFP. Median APC-
fluorescence intensities were set relative to non stimulated controls. 
 
Table 2.2. List of antibodies used for flow cytometry analysis. 
Antibody Label Source/Type Company / Cat.Nr. 
α-ICAM-1 IgG1 APC mouse (mc) BD Bioscience / 559771 
α-VCAM-1 IgG1 APC mouse (mc) BD Bioscience / 551147 
IgG1 isotype APC mouse (mc) BD Bioscience / 555751 
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2.1.6 Synthesis of surface-modified magnetic nanoparticles 
 
Synthesis of core−shell type iron oxide magnetic nanoparticles (MNP) has been performed 
in cooperation with Dr. Olga Mykhaylyk corresponding to a published protocol 
83
. To 
improve the physico-chemical and biological properties of the synthesised MNP, surface 
modification were carried out. Polyethylenimine-coated (PEI-Mag) MNP were generated 
by combining the fluorinated surfactant ZONYL
 
FSA (lithium-3-[2-
(perfluoroalkyl)ethylthio]propionate) with 25-kDa branched polyethylenimine. Silicon 
oxide-coated (SO-Mag) MNP were generated by condensation of tetraethylortho-silicate 
and 3-(trihydroxysilyl)propylmethylphosphonate resulting in a silicon oxide layer with 
surface phosphonate groups. The general physico-chemical properties of SO-Mag and PEI-
Mag MNP have been already described 
36, 84
 and are summarized in Table 2.3. 
 
Table 2.3. Physico-chemical characteristics of SO-Mag and PEI-Mag MNP. 
Characteristic SO-Mag MNP PEI-Mag MNP 
Coating Silicon-oxide Polyethylenimine 
ζ-Potential in ddH2O [mV] -38.0 ± 2.0 +55.0 ± 0.7 
Magnetic moment [fAm²] 8.7*10-5 5.8*10-5 
Iron weight per particle [µg Fe/particle] 6.2*10-13 1.4*10-12 
Core diameter [nm] 6.8 9.0 
Hydrodynamic diameter in ddH2O [nm] 40.0 ± 14.0 28.0 ± 2.0 
 
 
 
2.1.7 Production of lentiviral magnetic microbubbles 
 
As basis for the production of MMB, a phospholipid solution was prepared as previously 
described 
40
. To receive 10 ml of this phospholipid solution, 2 mg DPPE (1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine) and 10 mg DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine) kindly provided by Lipoid GmbH (Ludwigshafen, Germany) were given 
into a pear-shaped flask and 350 µl chloroform were added. The flask was attached to a 
rotary evaporation device (Rotavapor, Büchi Labortechnik, Essen, Germany) with 
connected vacuum pump. Phospholipids were allowed to completely dissolve by gentle 
rotation in a water bath (Weinkauf Medizintechnik, Forchheim, Germany) at 60°C for 10 
min without vacuum. The chloroform was then removed by vacuum-assisted evaporation 
for 1.5 h under permanent rotation in a water bath at 60°C. After complete drying, 
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phospholipids were dissolved in 10 ml of a sterile 10% glycerine solution by rotation at 
60°C for 10 min. The generated phospholipid solution was stored at 4°C for up to 3 month. 
To generate lentiviral MMB, MNP (SO-Mag or PEI-Mag) corresponding to a total iron 
weight of 150 µg or 250 µg were added to 1 ml phospholipid solution in 1.5 ml glass vials 
with screw caps and silicon/PTFE membranes (Omnilab, Bremen, Germany). The mixture 
was then covered with perfluorocarbon gas (Linde, Munich, Germany) and rapidly shaken 
for 20 s in a CapMix™ (3M ESPE, Neuss, Germany). Immediately before performing the 
experiment, lentiviral particles were added to the MMB solution in an optimal 
lentivirus:iron ratio given in Table 2.4. Lentivirus-MMB complex formation was left to 
occur for 10 min before use. 
 
 
Table 2.4. Used LV:iron ratios and corresponding LV:MMB ratios. 
LV 
optimal LV:iron 
ratio 
LV:MMB ratio 
(150 µg Fe/ml MMB) 
LV:MMB ratio 
(250 µg Fe/ml MMB) 
GFP 3.3*105 IP/µg Fe 5*106 IP/ml  
SHP-2 WT/CS/E76A 3.3*105 IP/µg Fe 5*106 IP/ml - 
pCHIV.eGFP 3.3*106 VP/µg Fe 5*107 VP/ml - 
veffLuc 3.3*106 VP/µg Fe 5*107 VP/ml 8.3*107 IP/ml 
VEGF 3.3*106 VP/µg Fe 5*107 VP/ml 8.3*107 IP/ml 
MMB containing 150 Fe µg/ml were used for all in vitro experiments. For in vivo experiments 250 
µg Fe/ml MMB were used. 
LV: lentivirus, Fe: iron, IP: infectious particle, VP: viral particle. 
 
 
2.1.8 Characterisation of physico-chemical properties of MMB 
 
Diameter (µm) and density (MB/ml) of MB in solution with or without associated MNP 
(SO-Mag or PEI-Mag) and lentiviruses (pCHIV.eGFP) were measured in 1:1000 dilutions 
in HBSS using a Casy Counter (Schärfe Systems, Roche Diagnostics, Mannheim, 
Germany). Mean iron content (µg Fe/MMB) and MNP content (MNP/MMB) were 
calculated from MMB densities (MB/ml). ζ-potentials of MMB, MNP and lentivirus in 
HBSS or serum were measured by photon correlation spectroscopy using a Malvern 3000 
HS Zetasizer (Malvern, Herrenberg, Germany). 
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2.1.9 Visualization of Lentivirus-MMB complex formation 
 
Lentivirus-MMB complex formation was visualized by fluorescence microscopy (Axiovert 
200M microscope, Zeiss, Jena, Germany) using fluorescence-labelled pCHIV.eGFP 
lentiviral particles. Lentiviral MMB were given on a microscope slide and covered with a 
glass coverslip (Menzel, Braunschweig, Deutschland). Transmission light and fluorescence 
images were taken at 63-fold magnification (Plan-Apochromat 63x/1.4 oil immersion 
objective, Zeiss). Complex formation between pCHIV.eGFP and MMB was furthermore 
verified by flow cytometry. Therefore, MMB solutions with or without addition of 
lentiviruses were diluted 1:100 in HBSS and analyzed using a FACS Canto II (BD 
Biosciences). Median GFP-fluorescence intensities of lentivirus MMB complexes were 
detected in the FITC-channel. 
 
 
2.1.10 MMB magnetizability and lentivirus binding capacity 
 
To analyse if the generated MMB are capable to completely associate the applied lentiviral 
particles, GFP LV (5*10
6
 IP/ml MMB) were incubated with MMB solutions (150µg Fe/ml) 
for 10 min. Mixtures were then exposed to a magnetic field for 15 min resulting in the 
generation of a MMB-free supernatant and concentrated lentiviral MMB. Meanwhile, 
medium on HUVEC cultured in 6-well plates (Sarstedt) was exchanged by HBSS. The 
MMB-free supernatants as well as the lentivirus-MMB concentrates were applied to 
HUVEC in separate wells. Culture plates were subsequently placed on top of a neodymium 
iron boron magnet (IBA Bio TAGnology, Goettingen, Germany) and US (2 W/cm², 1 
MHz, 50% duty cycle; Sonitron, Rich-mar, Schwaebisch Gmuend, Germany) was applied 
for 30 s by submerging the transducer into the solution. After 30 min of incubation on the 
magnetic plate, cells were washed once with PBS+ and provided with HUVEC growth 
medium. GFP expression was visualized 72 h later by fluorescence microscopy (Axiovert 
200M microscope, Zeiss) taking images at 10-fold magnification. Additionally, percentage 
of GFP-expressing cells was quantified by detaching cells with trypsin/EDTA and analysis 
by flow cytometry using a FACS Canto II (BD Biosciences). 
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2.1.11 Velocity and magnetic moment measurements of MMB 
 
Magnetic responsiveness measurements to determine velocity and magnetic moment of the 
MMB under a magnetic field with a magnetic gradient of approximately 7.8 T/m were 
performed in cooperation with Dr. Alexandra Heidsieck from the IMETUM (Technical 
University, Munich) as described before 
85
. 
 
 
2.1.12 Validation of the lentiviral MMB technique under static conditions in vitro 
 
The individual gene transfer efficiencies of the two MMB types in combination with the 
whole targeting procedure, comprising MF and US application, were tested under static 
conditions using HUVEC. Therefore, medium on HUVEC cultured in 12-well plates was 
exchanged by HBSS and the well dish was placed on a magnet plate. Meanwhile, GFP LV 
was incubated with MMB solutions (150 µg Fe/ml). 2 µl of the lentivirus-MMB complexes 
(corresponding to 1*10
4
 IP) were added to each well and ultrasound (30 s, 2 W/cm
2
, 1 
MHz, 50% duty cycle) was applied. After treatment, cells were further incubated on the 
magnet plate for 30 min at 37°C. Cells were then rinsed with PBS+ and cultured in 
HUVEC growth medium for 72 h before detection of GFP expression by fluorescence 
microscopy and flow cytometry. Untreated cells as well as cells incubated with 1*10
4
 IP of 
GFP LV for 30 min were analyzed as controls. To assess the individual contribution of 
MMB, MF or US to the whole lentiviral MMB technique, these single method parameters 
were omitted from the procedure, which was otherwise kept the same. 
 
 
2.1.13 Validation of the lentiviral MMB technique under flow conditions in vitro 
 
To test the ability of the lentiviral MMB to be targeted by MF and US under flow 
conditions, perfusion experiments with HUVEC were performed. Therefore, HUVEC were 
grown to confluence in channel slides (µ-slides IV
0.4
, IBIDI, Martinsried, Germany), which 
allow for the application of defined flow conditions. Channels were centrally placed above 
a magnet and were connected to a HBSS-filled syringe avoiding air inclusions. Perfusion of 
cells with HBSS was done at shear rates of 1, 5 or 7.5 dyn/cm
2
 using a syringe pump 
(kdScientific, Holliston, MA, USA). For each channel, 20 µl of MMB solution were 
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preincubated with veffLuc LV (1*10
5
 VP) for 10 min following 1:10 dilution in HBSS. 
Under continuous perfusion, lentivirus MMB complexes were slowly injected upstream of 
the cells into the tubing system. US (30 s, 1 MHz, 2 W/cm
2
, 50% duty cycle) was applied 
at the site of MF exposure. After 2 min perfusion HUVEC growth medium was added and 
slides were incubated for 72 h to allow for transgene expression. To assess the individual 
contribution of MF or US to the efficiency of the whole lentiviral MMB technique under 
flow, each of these two method parameters was omitted from the procedure, which was 
otherwise kept the same. Furthermore, 20 µl of MNP-lipid mixture incubated with GFP LV 
were perfused over HUVEC and targeted as described. Luciferase activity was detected 
after application of VivoGlo™ luciferin (0.5 mg/ml in PBS+; Promega, Madison, USA) 
using an IVIS imaging system from PerkinElmer (Waltham, MA, USA) at different 
exposure times. Transduction efficiencies were quantified by measurement of pixel density 
using the Hokawo software (Hamamatsu Photonics, Hamamatsu City, Japan). 
 
  
 
2.1.14 MTT assay 
 
To assess if the lentiviral 
cells, the MTT assay was performed
allows for quantification of the metabolic activity of cells 
reduce the yellow MTT (3-
its insoluble purple formazan
associated to cell viability this assay 
In detail, HUVEC cultured in 24
combined components of the lentiviral MMB technique (
Mag/SO-Mag MMB ± MF ± US) as described under 
was removed and 500 µl of MTT solution (5 mg/ml in DMEM without phenolred; Sigma
Aldrich) were added to each well. Plates were placed in the incubator for 2 h and cells were 
washed with PBS+ afterwards. Generated formazan crystals were dissolved by addition of 
100% 2-Propanol and 100 µl of the solution were transferred to a 96
Absorbance and background was measured at 550 nm and 620 nm, respectively, in a 
microplate reader (Spectra Fluor, Tecan, Maennedorf, Switzerland). Background was 
subtracted and absorbance values were 
Figure 2.1. Molecular principle
In living cells, the yellow-coloured MTT becomes reduced to its purple
NAD(P)H-dependent cellular oxidoreductase enzymes
of the formed formazan by absorbance measurements allows for indirect detection of cell viability.
(Scheme adapted from Rogan Grant 
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76
. This colorimetric assay 
by detecting their ability to 
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2.1.15 Identification of the cellular uptake mechanism responsible for lentiviral MMB 
mediated transduction 
 
To identify the responsible mechanism of uptake relevant for lentiviral MMB-mediated 
gene delivery, HUVEC were incubated with specific inhibitors of different endocytic 
pathways previous to SO-Mag MMB mediated transduction. Caveolae-mediated 
endocytosis was inhibited by incubation with 10 mM methyl-β-cxclodextrin (MβCD; 
Sigma-Aldrich). Inhibition of phagosome-lysosome fusion was accomplished by 
incubation with 10 nM ammoniumchloride (NH4Cl, Sigma-Aldrich) and 10 µM 
Cytochalasin B (CytoB, Sigma-Aldrich) were used to inhibit the clathrin-mediated 
endocytic pathway. All three inhibitors were diluted in DMEM supplemented with 20% 
FCS and 1% penicillin/streptomycin and preincubated on cells for 30 min. Lentiviral 
MMB were prepared and the transduction procedure was conducted as described under 
section 2.1.12. Afterwards, cells were washed once with PBS+ and maintained with 
HUVEC growth medium. Percentage of GFP expressing cells indicating efficiency of virus 
uptake was detected 72 h after transduction by flow cytometry. 
 
Table 2.5. List of applied endocytic inhibitors and respective mechanism of action. 
Inhibitor Appl. conc. Mechanism 
Methyl-β-cyclodextrin 
(MβCD) 
10 mM 
Inhibits caveolae-mediated endocytosis by 
cholesterol extraction from the plasma membrane 
and prevention of lipid raft formation 
86
. 
Ammoniumchloride 
(NH4Cl) 
10 nM 
Inhibits phagosome-lysosome fusion by 
neutralizing the endosomal pH and prevention of 
viral entry dependent on vesicle acidification 
87
. 
Cytochalasin B 
(CytoB) 
10 µM 
Inhibition of clathrin-mediated endocytosis by 
actin-depolymerization preventing vesicle 
trafficking 
88
. 
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2.1.16 Localized transduction of aortic endothelium by lentiviral MMB 
 
For the lentiviral SO-Mag MMB mediated transduction of vascular endothelium, thoracal 
aortas were isolated from C57BL/6J wild type mice (Charles River, Burlington, MA, 
USA). Therefore, the mouse was euthanized by cervical dislocation and the thorax was 
opened to expose the aorta. The thoracal aorta was carefully separated from connective 
tissue and intercostal arteries were cauterized to prevent leakage. The aorta was bilaterally 
catheterized with a polyethylen tube (Di=0.28 mm, Do=0.61 mm; SIMS Portex, Kent, UK) 
and mounted above a magnet in a recirculation system constructed for MMB-mediated 
transduction as depicted in Figure 2.2. Aortas (diameter ~1 mm) were perfused with 
serum-free DMEM at around 7-8 dyn/cm². 200 µl of lentiviral MMB (corresponding to 
1*10
6 
IP or 1*10
7 
VP) were diluted 1:5 in HBSS and slowly injected into the plastic tube 
upstream of the perfused aorta. US (30 s, 1 MHz, 2 W/cm
2
, 50% duty cycle) was applied 
simultaneously at the site of MF application. After further 5 min of perfusion and MF 
exposure the aorta was placed in 500 µl DMEM supplemented with 20% FCS in a 12-well 
plate and maintained in a humidified incubator. To visualize the local transduction of 
vascular endothelium achieved with the SO-Mag MMB technique under flow conditions, 
GFP LV-MMB complexes were used and immunofluorescence staining was performed 6 
days after transduction (see section 2.1.17). To analyse if the lentivirus-MMB mediated 
gene transfer is also capable to induce physiological effects in aortic endothelium, SO-Mag 
MMB complexed with VEGF LV or SHP-2 WT/CS/E76A LV were applied. Effects were 
analyzed by qRT-PCR (see Section 2.1.18), ELISA (see Section 2.1.19) and aortic ring 
sprouting assay (see Section 2.1.20) 3 days after transduction. 
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Figure 2.2. Schematic illustration of the perfusion setup applied to achieve localized lentiviral 
MMB mediated transduction of aortic endothelium. 
The isolated aorta was continuously perfused with DMEM. Lentiviral MMB were injected in the 
upstream tubing with simultaneous application of MF and US targeted to the central section of the 
vessel. 
 
 
2.1.17 Immunofluorescence staining of mouse aortas 
 
To assess localized transgene delivery by lentiviral MMB, GFP expression in whole mouse 
aortas was visualized by fluorescence microscopy (Leica DMI4000B, Leica Microsystems, 
Wetzlar, Germany). Immunofluorescence staining was performed in cooperation with 
Staffan Hildebrand from the University Bonn (AG Prof. Pfeiffer). Briefly, aortas were 
fixed for 1 h in 2% PFA, left in 20% sucrose over night, embedded in OCT, and frozen at -
80°C. 5 µm cross-sectional slices were cut with a cryotome and blocked for 30 min with 
5% BSA in PBS-T (0.1% Tween-20). To stain endothelial cells, slices were incubated with 
a PECAM-1 antibody (1:100 dilution in PBS-T supplemented with 1% BSA) overnight. 
Sections were washed thrice with PBS-T and the secondary antibody dilution (1:500 in 
PBS-T supplemented with 1% BSA) was incubated for 2 h. After another three washing 
steps, the sections were incubated with Hoechst nuclear stain (50 µg/ml in PBS). The 
sections were then washed once more, and mounted under a coverslip. Fluorescence 
pictures were taken at 20-fold magnification. 
 
Table 2.6. List of antibodies used for immunofluorescence staining of aortic cross sections. 
Antibody Label Source Company / Cat.Nr. 
α-PECAM-1 IgG2a, κ - rat BD Bioscience / 553370 
α-rat IgG (H+L) Alexa Fluor®555 goat Life Technologies / A-21434 
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T……...treated sample 
C……...untreated sample (control) 
target.…target gene 
HK……housekeeping gene (18S rRNA) 
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2.1.18 RNA isolation from mouse aortas and quantitative real-time PCR 
 
RNA from isolated mouse aortas was extracted using the peqGOLD Total RNA Kit from 
peqLab (Erlangen, Germany). Therefore, aortas were mechanically ground in RNA lysis 
buffer by addition of Precellys ceramic beads (Peqlab) and intense shaking in a CapMix 
(3M ESPE) for 20 s. Lysates were transferred to fresh tubes on ice and remaining chunks 
were removed by centrifugation at 10.000 g for 10 min at 4°C. RNA extraction from 
supernatants was performed following the manufacturer’s instructions and concentrations 
were measured using a Qubit and the corresponding detection reagent (ThermoFischer 
Scientific, Waltham, USA). Reverse transcription and quantitative real-time PCR (qRT-
PCR) were performed in cooperation with Dr. Andrea Riberio (Universitätsklinikum 
München) using the TaqMan real-time PCR system (Applied Biosystems) and 
corresponding probes (see Table 2.7). 
 
Table 2.7. Lists of commercial and self-made TaqMan-probes used for qR-TPCR. 
Probe NCBI Ref.Seq. Company / Cat.Nr. 
murine ICAM-1 NM_010493.2 
Applied Biosystems / 
Mm00516023_m1 
murine VCAM-1 NM_011693 
Applied Biosystems / 
MVCAM1-EX5 
murine 18S rRNA X03205.1 Applied Biosystems / 4310893E 
 
Probe Primer / Probe Sequences Company 
human VEGF 
fw: GCCTTGCTGCTCTACCTCCAC 
rv: ATGATTCTGCCCTCCTCCTTCT 
probe: AAGTGGTCCCAGGCTGCACCCAT, FAM 
Applied Biosystems 
 
 
Obtained Ct-values (Cycle of threshold) were used to calculate the relative gene 
expression according to the ∆∆Ct-method using the following formula: 
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2.1.19 Detection of VEGF levels in supernatants of transduced mouse aortas 
 
Amounts of VEGF generated by the endothelium of isolated mouse aortas which were 
transduced with VEGF LV-MMB complexes (see Section 2.1.16) were quantified using a 
human VEGF Quantikine
®
 ELISA (R&D Systems, Minneapolis, UK). Therefore, treated 
aortas were maintained for 72 h in DMEM supplemented with 20% FCS. The medium was 
then collected and VEGF concentrations were analyzed in duplicates following the 
manufacturer’s instructions. As control, VEGF levels in medium of aortas transduced with 
GFP LV instead of VEGF LV were analyzed in parallel. 
 
 
2.1.20 Aortic ring sprouting assay 
 
To assess the angiogenic capacity of aortic endothelial cells after lentiviral MMB treatment 
(VEGF LV or GFP LV), new vessel formation from aortic rings was detected. Therefore, 
the aortas were cut into small rings 72 h after transduction and the rings were carefully 
embedded in a growth factor reduced Matrigel Matrix (BD Bioscience). Incubation at 37°C 
in a humidified incubator for 30 min resulted in gelification of the previous free-flowing 
Matrigel. 200 µl DMEM supplemented with 20% FCS were added on top of the gel and 
the aortic rings were maintained in the incubator. The created semi-solid 3-D matrix 
supported sprout formation from the endothelium of the aortic rings. Pictures were taken 
48 h and 72 h after embedment. Angiogenic capacity was quantified by measuring the 
number of sprouting tips and the total area of vascularization. 
 
  
 
2.2 Protein biochemi
 
2.2.1 Protein extraction for western blot analysis and immunoprecipitations
 
Cells provided for western blotting
buffer purchased from Cell Signaling
min on ice. For SHP-2 activity measurements, cells were lysed in PTP lysis buffer
recipe see Section 2.2.4). Cells were scraped off the dish and passed twice through a 29G 
needle to ensure complete lysis. Lysates were cleared by centrifugation at 14.000
min at 4°C (Eppendorf Microcentrifuge5815R, Hamburg Germany) and supernatants were 
transferred to a fresh tube on ice. Protein concentrations were either analy
afterwards or lysates were stored at 
 
 
2.2.2 Protein quantification
 
To assess the protein concentration of cell lysates the bicinchoninic acid assay (BCA; 
ThermoFischer Scientific) was performed following the manufacturer’s instructions. The 
assay is based on the biuret reaction where Cu
medium (see Figure 2.3). The addition of bicinchoninic acid results in the formation of a 
purple-coloured BCA/copper
and can be detected colorimetrically at 562 nm.
 
 
Figure 2.3. Molecular principle of the BCA kit
Under alkaline conditions, BCA/copper
protein content and can be detected by absorbance measurement
thermofisher.com) 
Bicinchoninic acid (BCA) sodium salt
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In detail, 10 µl of protein lysate were added in duplicates to a 96-well plate (Sarstedt). BCA 
solution was prepared and 200 µl were added to each well. The plate was covered and 
incubated for 30 min at 37°C in the dark. Absorbances were measured at 550 nm (Spectra 
Fluor, Tecan). To establish a protein standard curve, an albumin dilution series ranging 
from 0 to 2 µg/µl was run alongside of each protein measurement. Protein concentrations 
were then calculated according to the formula: 
y = mx+b, 
whereby the variables m (slope) and b (intercept with the y-axis) are given by the standard 
curve and y is the measured absorbance value. 
 
 
2.2.3 Western blot analysis 
 
To allow for specific analysis of single proteins, SDS-PAGE (sodium dodecyl sulphate-
polyacrylamide gel electrophoresis) was performed which facilitates the electrophoretic 
separation of different proteins depending on their molecular weight. Same amounts of 
protein (30 µg) were mixed with 4x loading dye and denatured at 95°C for 5 min on a 
heating block (Biozym Scientific, Hessisch Oldendorf, Germany). Samples were loaded 
onto a prepared 10% acrylamide gel placed in an electrophoresis apparatus (Peqlab) and 
covered with 1x running buffer. Electrophoresis was performed at 100 mV for 15 min 
following 200 mV until the loading dye front nearly reached the edge of the gel. Separated 
proteins were immediately transferred onto a nitrocellulose membrane (Peqlab) using a wet 
electroblotting system (Peqlab). Therefore, the acrylamide gel, nitrocellulose membrane, 
filter papers and sponges were soaked in 1x transfer buffer. The blotting sandwich was 
arranged in 1x transfer buffer as follows: 
 
Anode 
Sponge 
Filter papers 
Nitrocellulose membrane 
Gel 
Filter papers 
Sponge 
Cathode 
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Air inclusions disrupting proper protein transfer were removed carefully and the blotting 
sandwich was placed in the blotting tank filled with 1x transfer buffer. Protein transfer was 
accomplished at 50 V for 2 h. Afterwards, the blotting sandwich was disassembled and the 
membrane with immobilized proteins was checked for proper transfer by staining with 
Ponceau red solution for 3 min. The membrane was washed several times with distilled 
water and protein traces were analyzed for equability of protein load or disturbances during 
transfer before proceeding. Unoccupied binding positions on the membrane were then 
blocked by incubation in 1x TBS-T containing 5% milk for 1 h at room temperature. To 
detect proteins, the membrane was incubated with a primary antibody dilution (see Table 
2.8) over night at 4°C on a shaker. After washing the membrane thrice for 10 min with 1x 
TBS-T it was incubated with the respective horseradish peroxidase (HRP)-conjugated 
secondary antibody dilution (see Table 2.9) for 1 h at room temperature. The membrane 
was washed again thrice for 10 min with 1x TBS-T to remove any traces of unbound 
antibodies. The HRP signal was detected by incubating the membrane with luminol 
detection reagent and image acquisition at different exposure times depending on the signal 
intensity was performed using a bioluminescence imager (Hamamatsu Photonics, 
Hamamatsu City, Japan). Proteins of different molecular weight could be detected on the 
same membrane by consecutive antibody incubation. To verify equal protein loading and 
accomplish normalized protein quantification, the housekeeping protein β-actin was 
detected. Band intensities were assessed using the Hokawo software (Hamamatsu 
Photonics) and values were normalized to respective β-actin bands. 
 
→ SDS-PAGE (10%) 
10% Separation gel 
10%  Acrylamide:Bisacrylamide (30%:0.8%) 
375 mM 1.5 M Tris base, pH 8.8 
0.1%  10% SDS 
0.05%  10% APS 
0.005% TEMED 
APS (free radical source) and TEMED (catalyst) were added directly before casting the 
gel. The gel was covered with 500 µl 2-Propanol to achieve a plain gel edge and exclude 
aerial oxygen. The 2-Propanol layer was poured off after gel solidification. 
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4% Stacking gel 
4%  Acrylamide:Bisacrylamide, 30%:0.8% 
125 mM 500 mM Tris base, pH 6.8 
0.1%  10% SDS 
0.05%  10% APS 
0.005% TEMED 
APS and TEMED were added directly before casting the gel on top of the separation gel. A 
sample comb was placed in the stacking gel before solidification. 
 
→ 4x Loading dye 
250 mM Tris base 
8%  SDS 
40%  Glycerol 
0.02%  Bromphenol blue 
400 mM β-Mercaptoethanol 
Dye was directly diluted in the sample volume. 
 
→ 10x Running buffer (SDS-PAGE) 
 250 mM Tris base 
 1.92 M Glycine 
 10%  SDS 
Buffer was diluted with distilled water. 
 
→ 5x Transfer buffer (blotting) 
125 mM Tris base 
 1 M  Glycine 
20% Methanol was added upon dilution with distilled water. 
 
→ Ponceau red solution 
 5%  Acetic acid 
 0.1%  Ponceau-S 
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→ 10x TBS (Tris buffered saline) 
 500 mM Tris base, pH 7.4 
 1.5 M  NaCl 
0.1% Tween 20 was added upon dilution with distilled water (TBS-Tween, TBS-T). 
1x TBS-T was used for washing steps, blocking solution and antibody dilution. 
 
→ Luminol detection reagent 
 0.1 M  Tris base, pH 8.5 
 0.4 mM p-Coumaric acid 
2.5 mM Luminol 
 0.08%  H2O2, 30% 
H2O2 was added directly before detection. 
 
 
Table 2.8. List of primary antibodies used for western blot analysis. 
Antibody Source/Type Company / Cat.Nr. 
α-β-actin (13E5) rabbit mc Cell Signaling Technlogy / 4790 
α-pAKT (S473) (D9E) rabbit mc Cell Signaling Technlogy / 4060 
α-VCAM-1 rabbit mc Cell Signaling Technlogy / 12367 
α-ICAM-1 (H-108) rabbit mc Santa Cruz Biotechnology, Inc. / sc-7891 
α-GAPDH (6C5) mouse mc Merck Millipore / MAB374 
mc: monoclonal 
 
 
Table 2.9. List of secondary antibodies used for western blot analysis. 
Antibody Label Source Company/ Cat.Nr. 
α-Mouse IgG  HRP goat Merck Millipore / 12-349 
α -Rabbit IgG  HRP goat Merck Millipore / 12-348 
HRP: horseradish-peroxidase 
 
  
 
2.2.4 Immunoprecipitation 
 
The phosphatase activity of 
HUVEC was assessed using the pNPP
proteinaceous, non-specific
phosphatases 
89
. The principle of the assay is
catalyze the hydrolysis of p
with absorbance at 405 nm.
 
Figure 2.4. Molecular principle of the pNPP assay
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To measure the activity of one specific phosphatase its purification by immunoprecipitation 
from the cell lysate is necessary previous to incubation with the 
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37°C in the dark under gentle agitation to enable an optimal enzyme reaction. Afterwards, 
the mixture was applied to the separation column placed in the magnetic separator and the 
cleared flow through was collected in a tube. 100 µl of the flow through were transferred to 
a 96-well plate and absorbance was measured at 405 nm (SpectraFluor, Tecan). As blank, 
100 µl of pNPP substrate solution were always measured in parallel. Blank values were 
subtracted and absorbances were normalized to untreated control values. To inhibit the 
basal phosphatase activity of SHP-2 the general phosphatase inhibitor Na3VO4 (25mM; 
Sigma-Aldrich) or the specific SHP-2 inhibitor PtpI IV (2 µM; Merck Millipore, 
Darmstadt, Germany) were added to the substrate solution previous to incubation with 
precipitated SHP-2. 
 
Table 2.10. Antibodies used for immunoprecipitations. 
Antibody Source Company/ Cat.Nr. 
α-human SHP-2 (H-2) Goat Santa Cruz / sc-271550 
α-Myc-Tag (71D10) Goat Cell Signaling Technology / 2278 
 
 
→ PTP lysis buffer 
150 mM NaCl 
50 mM 1 M Tris-HCl, pH 7.4 (Tris –base equilibrated with HCl) 
5 mM  EDTA 
1:500  Proteinase Inhibitor Cocktail (Sigma-Aldrich) 
0.5%  Nonidet P-40 (NP-40) 
0.1%  Deoxycholic acid (DOC) 
0.1%  SDS 
1mM  NaVO3 
PTP lysis buffer was freshly prepared in distilled water and brought to pH 7.35. 
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→ Phosphatase buffer 
24 mM HEPES 
120 mM NaCl 
Phosphatase buffer was prepared in distilled water, brought to pH 7.4 and could be stored 
at 4°C for up to 2 month. 
 
→ pNPP (p-nitrophenylphosphate) substrate solution 
 12.5 mM pNPP 
 5 mM  DTT 
pNPP was purchased as 5 mg tablet which was dissolved in 900 µl phosphatase buffer with 
DTT directly before use. As the substrate solution was diluted by the void volume of the 
separation columns (30 µl) the final concentration in the assay was 10 mM. The solution 
was protected from light throughout the procedure. 
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2.3 In vivo Experiments 
 
2.3.1 Study approval and general mouse housing conditions 
 
All animal studies were conducted in accordance with the German animal protection law 
and approved by the district government of upper Bavaria (Regierung von Oberbayern, 
approval reference number AZ55.2-1-54-2532-172-13 and AZ55.2-1-54-2532-36-2015). 
The investigations conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 
1996). 
The animal experiments were performed with 16-24 week old male and female C57 BL/6J 
wild type mice purchased from Charles River (Sulzfeld, Germany). Mice were kept in 
individually ventilated cages (IVC, Techniplast, Germany) under a 12 h day-night cycle 
with dusk/dawn imitation. Animals had free access to water and laboratory chow and were 
provided with mouse houses and cotton fibre nestlets as cage enrichments. Room 
temperature was kept between 22-23°C and humidity was 50%. Health management and 
general maintenance was performed by the staff of the animal facility. Due to special 
safety regulations and requirements regarding the conduction of S2 animal experiments 
and housing conditions for S2 animals, the procedures described in Section 2.3.2 to 2.3.4 
were partially performed in the S2 animal facility of the Klinikum Rechts der Isar (TU 
Munich). Mice injected with lentiviral MMB were classified as S2 organisms until 48 h 
after transduction and were subsequently downgraded to S1 level as no residual or excreted 
lentiviral particles could be found in different body fluids (see Section 2.3.9). To ensure 
tight monitoring, mice were inspected daily and the condition of every mouse was reported 
in specific score sheets from beginning of the experiment to euthanasia of the animal. 
Experiments were prematurely abrogated if the score of a mouse reached a certain score 
level predetermined in the animal test proposal. 
  
MATERIAL & METHODS | 40 
 
2.3.2 Anaesthesia, antagonisation and analgesia 
 
All surgical procedures were performed under deep anaesthesia achieved by intraperitoneal 
(i.p.) injection of Midazolam (5 mg/kg body weight), Medetomidin (0.5 mg/kg body 
weight) and Fentanyl (0.05 mg/kg body weight) in 0.9% NaCl. After reaching surgical 
tolerance, as verified by loss of the conjunctival and pedal withdrawal reflexes, 
experimental procedures were started. Bepanthen salve (Bayer, Leverkusen, Germany) was 
applied to the eyes to avoid eye damages through desiccation. To achieve fast awakening 
after surgeries, antagonisation of anaesthesia was performed by subcutaneous (s.c.) 
injection of Flumazenil (0.5 mg/kg body weight) and Atipamezol (2.5 mg/kg body weight) 
in 0.9 % NaCl. Postsurgical analgesia was provided by s.c. injection of 0.065 mg/kg body 
weight Buprenorphin with the first injection 10 min before injection of the antagonisation 
following administration in a 12 hour-cycle until 3 days after lentiviral MMB application. 
Additionally, mice were provided with 300 µl NaCl by s.c. injection to ensure sufficient 
rehydration. Throughout the procedures mice were placed on a 40°C heating plate to 
prevent cooling until complete recovery and were subsequently transferred back to their 
cages.  
 
 
2.3.3 Preparation of the dorsal skin 
 
The implantation of a dorsal skinfold chamber (DSFC) is an established animal model 
enabling long-term follow up of the dorsal vascular bed in living animals via intravital 
microscopy 
90
. One major advantage is given by the fact that the implanted observation 
chamber allows for repeated microscopic access in restrained animal without anaesthesia. 
As fixture for the dorsal skinfold serves a pair of inverse titanium frames (Figure 2.5.a). 
The front frame comprises a circular observation window in which a coverslip (ø 11.8 mm, 
Menzel, Braunschweig, Germany) is inserted. The back frame comprises three screws for 
fixation of the frame sandwich. To implant the DSFC, mice were anesthetized (see Section 
2.3.2), the hair on the back area was trimmed (Aesculap, Braun) and the skin was depilated 
using a chemical depilation creme (Pilcamed, Schwarzkopf). Loose fur and depilation 
creme were completely removed with warm water and the skin was disinfected with 70% 
ethanol. The back skin was strained and the back frame was attached by non-absorbable 
suture (silk, 5/0; FST). The lower screws of the back frame were passed through the skin 
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via two holes pierced with a cannula. Using an operation microscope (Stemi 2000-CS, 
Zeiss) and sterile surgical instruments (FST) the skin layer on the front side was removed 
in a circular area matching the window area of the front frame (ø 14 mm). Connective 
tissue was removed from the exposed subcutaneous vascular bed to achieve maximal 
microscopic resolution. The front frame was then attached to the screws of the back frame 
whereby complete closure of the opened skin area and adhesion to the coverslip had to 
occur. Both frames were fixed by suture. Representative pictures of the completely 
implanted DSFC and the resulting exposed microcirculation are shown in Figure 2.5.b. 
Antagonisation, analgesia and follow-up care were done as described in Section 2.3.2. 
Maximal two mice with DSFC were maintained in one cage without houses and 
moisturized chow was provided in a petri dish placed on the ground. Catheterization and 
lentiviral MMB mediated transduction were performed 24 h after DSFC implantation to 
allow for proper equilibration of blood flow in the window area. 
 
 
 
Figure 2.5. The dorsal skinfold chamber (DSFC) model in mice. 
(a) From left: Titanium frames, screws and circlip used for the implantation of the DSFC. Scale bar 
indicates 1 cm. (b) A mouse implanted with a DSFC. The resulting observation window (ø 14 mm) 
allows for macro- and microscopic visualization of vessels of the dorsal skin. 
 
 
 
2.3.4 Catheterization of the Arteria carotis 
 
To assure that a large quantity of lentiviral MMB reaches the vessels of the dorsal skin 
within the first round of circulation, the Arteria carotis was chosen as site of injection. To 
place the catheter, the mouse was anesthetized and placed in dorsal position on a special 
operation table featuring a slot for the implanted DSFC. The throat area was amply 
disinfected and the skin was cleanly opened by a single cut (15-20 mm). The right Arteria 
carotis communis was freed from surrounding tissue and the vagus nerve and blood flow 
was disabled by application of a cardial clamp and cranial ligation by suture. The vessel 
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was opened with a microscissor and the catheter (Di=0.28 mm, Do=0.61 mm; SIMS 
Portex) connected to a 1 ml syringe filled with NaCl was inserted in cardial direction and 
fixed with three suture straps. The cardial clamp was removed and injection of lentiviral 
MMB could be performed as described in Section 2.3.5. After conduction of the 
transduction procedure, the Arteria carotis was cardially ligated by suture and the catheter 
was removed. The skin incision was closed by suture and antagonisation, analgesia and 
follow-up care were done as described in Section 2.3.2. Upon recovery, mice were 
carefully monitored to exclude any neuromuscular dysfunctions resulting from the ligation 
of the Arteria carotis or the injection procedure. 
 
 
2.3.5 Injection of lentiviral MMB via the Arteria carotis catheter 
 
The experimental aim was to target the lentiviral MMB injected via the Arteria carotis to 
the vascular endothelium of the dorsal skin by simultaneous application of a strong 
magnetic field (MF) and ultrasound (US). To do so, the anaesthetized mouse implanted 
with the DSFC and catheterized as described in the Sections 2.3.3 and 2.3.4 was placed on 
a stage on top of an electromagnet in left lateral position (2.6.a and b). The magnetic tip 
was thereby directly pointing to the middle of the DSFC window with a distance of 2-3 
mm. A droplet of NaCl was applied onto the closed observation window to allow for 
efficient transduction of the ultrasonic waves to the vessels of the dorsal skin. 100 µl of 
SO-Mag MMB were incubated with veffLuc LV (8.3*10
7
 VP/ml, respectively) for 10 min 
and drawn up into a 1 ml syringe. The electromagnet (1039 mT) was switched on, 
lentiviral MMB were slowly injected (20 s) and US was applied for 30 s (2 W/cm², 1 MHz, 
50% duty cycle). The MF was applied for further 5 min before the mouse was transferred 
back to the surgical stage to remove the catheter as described in Section 2.3.4. 
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Figure 2.6. Experimental setting applied for targeted transduction using lentiviral MMB. 
(a) Schematic illustration of the setup implemented for lentiviral MMB targeting in vivo. The 
observation window of the DSFC was centred between the tip of an electromagnet and the US 
transducer. During injection of the lentiviral MMB via the Arteria carotis catheter, MF and US 
were simultaneously applied to achieve localized transduction of vascular endothelial cells. (b) 
Actual experimental setting of the lentiviral MMB technique in vivo. Modified from Mannell et al. 
40
. 
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2.3.6 Bioluminescence imaging 
 
To assess the systemic distribution of transgene expression resulting from veffLuc LV-
MMB transduction, luciferase activity was detected 7-10 days after the procedure. The 
mouse was anaesthetized and luciferin was applied via i.p. injection (100 µl, 3 mg/ml in 
0.9% NaCl). After placing the mouse in the preheated acquisition chamber (37°C) 
bioluminescence was detected at different exposure times using an IVIS imaging system 
from PerkinElmer (Waltham, MA, USA). Afterwards, mice were euthanized by cervical 
dislocation under existing anaesthesia and bioluminescence of isolated organs was assessed 
by placing these in a petri dish. 
 
 
2.3.7 DNA isolation from mouse tissue and quantification of proviral genome copy 
numbers 
 
Genomic DNA was extracted from mechanically homogenized tissues (dorsal skin tissue, 
livers and lungs) of mice receiving lentiviral MMB with or without MF and US targeting 
using the NucleoSpin
®
 Tissue gDNA Kit (Macherey-Nagel). The provirus genome copy 
numbers per cell were assessed by using the Lenti-X™ Provirus Quantitation Kit 
(Macherey-Nagel) following the manufacturer’s instructions. 
 
 
2.3.8 MNP detection in organs 
 
The systemic distribution of MNP in lentiviral MMB treated mice was assessed by 
magnetic particle spectroscopy (MPS) in cooperation with Dr. Dietmar Eberbeck from the 
Physikalisch-Technische Bundesanstalt (PTB), Berlin. Organs were isolated, minced and 
added to 0.5 ml tubes (Applied Biosystems). Only non-metallic (iron-free) instruments 
were used for these preparations to avoid any sample contamination. MPS measurements 
were performed as described before 
91
. 
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2.3.9 p24 core protein ELISA 
 
To analyse if any lentiviral particles remain or are secreted 48 h after lentiviral MMB 
mediated transduction, a LentiX™ p24 Rapid Titer Kit (Clontech, California, USA) was 
performed according to the manufacturer’s instructions. The ELISA kit allows for sensitive 
detection of HIV-1 p24 core protein in sample supernatants. Saliva smears and smears of 
the catheter wound were collected with moist cotton swabs. Urine was collected with a 
pipette, faeces were collected from the cage and whole blood was drawn from the Vena 
cava to gain plasma. Cotton swabs and faeces were soaked and vortexed in 300 µl PBS 
following centrifugation (14.000 g, 10 min) to gain a clean supernatant. Each sample (100 
µl) was exposed in duplicates to the p24 ELISA. PBS containing 2.3*10² VP of GFP LV 
was measured alongside as positive control. 
 
 
2.4 Statistical analysis 
 
Statistical analyses were performed using Sigma Stat version 3.5. For multiple 
comparisons of normal distributed data sets the one-way analysis of variance (1-way 
ANOVA), followed by Student-Newman-Keuls post-hoc test was performed. The unpaired 
Student’s t-test was used for the comparison of two normal distributed independent groups. 
For comparison of two not normally distributed independent data sets the Mann-Whitney 
Rank Sum Test was performed. Differences were considered significant at an error 
probability level of *p≤0.05. All data are presented as means ± standard error of the mean 
(SEM).
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3 Results 
 
3.1 Characterisation and comparison of SO-Mag and PEI-Mag MMB in vitro 
 
3.1.1 Integration of SO-Mag and PEI-Mag magnetic nanoparticles into MMB 
 
An important prerequisite for the successful generation of a multi component carrier 
system is the complete cooperation of the single components with each other. In case of the 
MMB, the stable and evenly uptake of magnetic nanoparticles (MNP) into the MB lipid 
shell is essential to create an effective targeting system. This might be influenced by 
different factors, including composition of the phospholipid solution, surface charge of the 
nanoparticles or ionic strength of the surrounding medium. The phospholipid solution 
containing DPPE and DPPC used in this study has been established and verified before 
40, 
41
 as has been its combination with the positively charged PEI-Mag MNP (PEI-Mag 
MMB). In this study a new type of MMB coupled to SO-Mag MNP (SO-Mag MMB) was 
generated. To allow for a rational comparison, MMB containing equimolar concentrations 
of iron (150 µg Fe/ml lipid solution) were prepared. Both MMB types displayed the typical 
feature of floating to the surface within 1-5 min indicating that gas filled bubbles were 
formed (Figure 3.1.a; n=3). In case of the SO-Mag MMB this floating process occurred 
more rapidly (1 min). The PEI-Mag MMB floated slower and the solution remaining below 
did not clear off completely within 5 min as was the case with SO-Mag MMB. 
Importantly, after floating to the surface, SO-Mag and PEI-Mag MMB could be easily 
redistributed into the solutions by gentle agitation. To test the magnetic responsiveness of 
both MMB types, they were exposed to a sideward magnetic field (MF). SO-Mag and PEI-
Mag MMB were both attracted towards the MF, whereby SO-Mag MMB were attracted 
more rapidly (1 min) leaving a clear microbubble-free solution (Figure 3.1.b; n=3). PEI-
Mag MMB in contrast, accumulated only slowly and incompletely at the site of MF within 
5 min of exposure (Figure 3.1.b; n=3). 
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Figure 3.1. SO-Mag MNP show a better MMB association than PEI-Mag MNP. 
(a) After preparation, MMB in both solutions rose to the surface, whereby this process was faster 
and more complete with SO-Mag MMB compared to PEI-Mag MMB. n=3. (b) When exposed to a 
sideward magnetic field, SO-Mag MMB were quickly attracted whereby the remaining solution 
was optically free of bubbles or MNP. PEI-Mag MMB, in contrast, responded slower to MF 
application and did not completely accumulate at the site of MF within 5 min. n=3. 
 
 
3.1.2 General physico-chemical characteristics of MMB 
 
The size of a single carrier component can be decisively for successful gene delivery, 
especially if applied in vivo via the circulatory system. In case of MMB, too large bubbles 
may cause obstructions within the smallest vessels leading to severe ischemic 
complications. Too small bubbles, in contrast, may incorporate too little amounts of MNP 
whereby their magnetic moment might be significantly reduced. Also the recognition and 
clearance by natural mechanisms, such as the reticuloendothelial system, is strongly 
depending on matters of size. Therefore, we assessed important physico-chemical 
parameters of the SO-Mag and PEI-Mag MMB listed in Table 3.1. After integration of SO-
Mag and PEI-Mag MNP, the mean diameter of the MMB increased by 20.80 ± 0.56% and 
12.09 ± 1.91%, respectively, compared to naked MB (*p≤0.05, n=3). By association of 
lentiviruses, however, diameter of both MMB types was decreased again, whereby no 
difference in mean diameter between PEI-Mag and SO-Mag MMB could be detected 
(Table 3.1; *p≤0.05, n=3). Despite the fact that SO-Mag and PEI-Mag MNP possessed 
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completely opposed ζ potentials (-16.1 ± 0.6 mV and 14.7 ± 1.2 mV, respectively) the 
resulting MMB complexes both exhibited a positive ζ potential as assessed in HBSS. 
Therefore, interactions between both MMB types and the negatively charged lentiviruses (-
8.8 ± 0.6 mV) might predominantly occur via electrostatic interactions. Calculations of the 
average number of MNP embedded in one MMB revealed that one single SO-Mag MMB 
contained significantly higher amounts of MNP than PEI-Mag MMB (Table 3.1; *p≤0.05, 
n=3). 
 
 
Table 3.1. Physico-chemical properties of MB with and without associated MNP (150 µg 
Fe/ml) and lentiviruses (5*10
8
 VP/ml MMB). 
 LV Diameter [µm]a, b µg Fe/MMB
b MNP/MMBb, c ζ Potential [mV]b 
naked MB - 5.0 ± 0.2 - - 6.2 ± 0.3 
pCHIV.eGFP + 1.9 *10
-1 ± 0.8 *10-2 - - -8.8 ± 0.6 
SO-Mag MNP  - 4.0*10
-2  ± 1.4*10-3 d   -16.1 ± 0.6 
SO-Mag MMB - 6.1 ± 0.1 2.0*10
-8 ± 8.1*10-11 3.6*106 ± 2.5*10-4 3.9 ± 0.5 
 + 4.9 ± 0.5 4.4*10
-8 ± 8.1*10-9 6.2*106 ± 1.2*10-6 5.0 ± 0.2 
PEI-Mag MNP - 2.8*10
-2  ± 0.2*10-2 d - - 14.7 ± 1.2 
PEI-Mag MMB - 5.6 ± 0.2 2.5*10
-8 ± 1.5*10-9 1.7*106 ± 4.6*10-4 9.6 ± 0.5 
 + 4.7 ± 0.2 6.8*10
-8 ± 7.4*10-9 3.4*106 ± 2.4*10-5 9.4 ± 0.5 
a
 Particle diameter for MMB and lentivirus-MMB complexes, hydrodynamic diameter for sole 
pCHIV.eGFP LV;
 b
 mean ± SEM; *p≤0.05 vs. naked MB, 
#
p≤0.05 vs. MB+MNP, n=3 in 
duplicates; 
c
 MNP iron/particle content: 6.2*10
-13
µg Fe/SO-Mag MNP and 1.4*10
-12
µg Fe/PEI-
Mag MNP; 
d
 adapted from Almstätter et al. 
36
 
MNP: magnetic nanoparticles; MMB: magnetic microbubble; MB: microbubble; LV: lentivirus; 
Fe: iron. 
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3.1.3 Verification of lentivirus binding to MMB 
 
There are manifold options for genetic vectors to be used for gene therapy purposes. In this 
study we decided to use lentiviruses in combination with our MMB system, due to their 
unique infectious capacity and related high gene transfer efficiency. The capacity of PEI-
Mag MMB to complex lentiviruses has been shown before 
41
. To assess if the new SO-
Mag MMB are equally or even more efficient in binding lentiviruses, we incubated both 
MMB solutions with fluorescence-labelled lentiviral particles (pCHIV.eGFP LV) allowing 
the visualization by fluorescence microscopy and quantification using flow cytometry. As 
shown in Figure 3.2.a, SO-Mag and PEI-Mag MMB successfully associated the added 
pCHIV.eGFP LV to their outer shell (n=3). No lentiviral particles were thereby found 
within the MMB gas core. Flow cytometry analysis revealed a substantial increase in 
fluorescence of the MMB upon addition of pCHIV.eGFP LV. The quantitative analysis of 
these signals resulted in no difference between the MMB types indicating that the single 
SO-Mag and PEI-Mag MMB associate approximately the same amount of lentiviruses to 
their shell (3.2.b and c; *p≤0.05, n=4). 
 
 
 
Figure 3.2. Visualization of pCHIV.eGFP LV binding to SO-Mag and PEI-Mag MMB 
(a) Both MMB types were capable to associate the added lentiviral particles to their outer shell as 
visualized by fluorescence microscopy. n=3. (b) The quantitative analysis of this complex 
formation by flow cytometry showed that SO-Mag and PEI-Mag MMB were equally efficient in 
binding lentiviruses. *p≤0.05, n=4, 1-way ANOVA. (c) Representative dot plot overlays of MMB 
without and with incubated pCHIV.eGFP LV as well as the lentivirus alone. 
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3.1.4 Lentivirus binding capacity of the MMB 
 
After the general ability of MMB to bind lentiviruses was verified we sought to test if the 
added lentiviral particles are completely complexed by the MMB. This is important, as no 
free lentiviral particles should remain within the solution which may otherwise cause 
unspecific gene expression. To verify that SO-Mag and PEI-Mag MMB possess the 
capacity to indeed bind the optimal lentivirus amounts determined before (5*10
6
 IP/ml 
MMB), MMB and lentiviruses were incubated for 10 min. MMB solutions were then 
magnetically separated by exposure to an external MF for 15 min following separate 
application of the resulting MB free supernatant and MMB concentrate to cells. HUVEC 
treated with the supernatants from both MMB types exposed very low GFP expression 
indicating only marginal lentiviral particles remaining unbound by the MMB (Figure 3.3.a 
and b). In contrast MMB concentrates achieved very high transduction rates. Interestingly, 
lentiviral SO-Mag MMB achieved a higher transduction rate than lentiviral PEI-Mag 
MMB (*p≤0.05, n=6). As the absolute number of lentiviral particles bound to the MMB 
was the same for both MMB types (as shown in Section 3.1.3), this difference in 
transduction efficiency can only be explained by a better magnetic sedimentation of the 
SO-Mag MMB in the cell culture dish and therefore enhanced delivery of lentiviruses to 
cells compared to PEI-Mag MMB. 
 
 
 
Figure 3.3. Lentivirus uptake capacity of SO-Mag and PEI-Mag MMB. 
(a) GFP LV given to the MMB solution was nearly completely complexed by both MMB types as 
can be seen by the low GFP signal of cells incubated with the magnetically separated supernatants. 
Cells treated with the magnetically concentrated MMB portions exposed a strong GFP expression 
signal. This signal was significantly higher when SO-Mag MMB were used. *p≤0.05, n=6, 1-way 
ANOVA. (a) Representative fluorescence pictures of GFP expression in cells. Scale bar indicates 
500 µm.  
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3.1.5 Measurements of magnetic velocities and magnetic moments 
 
As described in the former section, SO-Mag MMB were found to deliver their lentiviral 
cargo to endothelial cells with higher efficiency than PEI-Mag MMB. To test if this effect 
might be due to superior magnetic properties of the SO-Mag MMB, velocities and 
magnetic moments of both MMB compositions (150 µg Fe/ml) were assessed by 
application of a magnetic field gradient. As depicted in Figure 3.4.a, SO-Mag MMB 
exposed a 1.6-fold higher velocity (peak at 19.10 ± 0.69 µm/s) compared to PEI-Mag 
MMB (peak at 11.40 ± 0.22 µm/s). This difference in magnetic potency became even more 
striking by calculation of the magnetic moments of the two MMB types, with SO-Mag 
MMB possessing an about three-fold higher magnetic moment than the PEI-Mag MMB 
(94.74 ± 0.47 fA m
2
 vs. 32.14 ± 0.12 fA m
2
, respectively; Figure 3.4.b). 
 
 
 
 
Figure 3.4. Velocity and magnetic moments of SO-Mag and PEI-Mag MMB under a 
magnetic field gradient. 
(a) SO-Mag MMB were found to exhibit an 1.6-fold higher velocity under a magnetic field 
gradient compared to PEI-Mag MMB. (b) This resulted in a nearly 3-fold higher magnetic moment 
of SO-Mag MMB. n=3. 
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3.1.6 Cytotoxicity of MMB and technical parameters 
 
We furthermore evaluated potential cytotoxicity of each method parameter applied during 
lentiviral MMB mediated gene delivery (GFP LV ± PEI-Mag/SO-Mag MMB ± MF ± US). 
Therefore, cell viability was assessed 72h after the respective treatment combination using 
the MTT assay. Application of lentivirus, MMB or MF alone did not change cell viability, 
indicating low cytotoxic effects of these components (Figure 3.5). Only the application of 
US induced slight cell toxicity by about 20% compared to untreated cells, regardless of the 
MNP type used (*p≤0.05, n=4 in triplicates). 
 
 
 
Figure 3.5. Detection of cytotoxic effects of the components of the lentiviral MMB technique 
using the MTT Assay. 
Application of SO-Mag and PEI-Mag MMB alone or with additional exposure to MF did not cause 
any cytotoxicity in endothelial cells. However, direct exposure to US reduced cell viability by 
around 20%. *p≤0.05, n=4 in triplicates, 1-way ANOVA. 
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3.1.7 Endocytic uptake mechanism accounting for lentiviral MMB mediated 
transduction 
 
We were furthermore interested to identify the responsible mechanism of uptake relevant 
for lentiviral MMB-mediated gene delivery to endothelial cells. Therefore, cells were 
treated with inhibitors of different endocytic pathways previous to MF and US assisted 
transduction using SO-Mag MMB complexed with GFP LV. Lentiviral uptake was 
measured by detection of the percentage of GFP expressing cells using flow cytometry 72 
h later. As shown in Figure 3.6, inhibition of caveolae-mediated endocytosis by methyl-β-
cyclodextrin (MβCD), significantly decreased lentivirus uptake compared to cells without 
inhibitor treatment (*p≤0.05, n=5 in duplicates). In contrast, inhibition of phagosome-
lysosome fusion by ammoniumchloride (NH4Cl) or inhibition of the clathrin-mediated 
endocytic pathway by Cytochalasin B (CytoB) did not influence lentiviral MMB mediated 
transduction. 
 
 
Figure 3.6. Identification of the cellular uptake mechanism relevant for MMB-mediated 
transduction. 
Inhibition of caveolin-dependent endocytosis with methyl-β-cyclodextrin (MβCD; 10 mM) resulted 
in severe impairment of lentiviral MMB mediated transduction efficiency (SO-Mag MMB with 
GFP LV). In contrast, inhibition of endosome-lysosome fusion by ammoniumchloride (NH4Cl; 10 
nM) or clathrin-dependent endocytosis by Cytochalasin B (CytoB; 10 µM) did not change GFP 
expression compared to the untreated controls. *p≤0.05, n=4, 1-way ANOVA. 
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3.1.8 Gene transfer efficiency of lentiviral MMB under static conditions in vitro 
 
To compare the gene transfer efficiencies of both MMB compositions, GFP LV coupled 
MMB were added to endothelial cell cultures following combined or separate application 
of MF (30 min) and US (30 s, 2 W/cm², 1 MHz, 50% DC). As control, cells were 
incubated with only GFP LV for 30 min. Flow cytometry analysis of GFP expressing cells 
revealed that application of lentivirus alone yielded only very low transduction rates (1.8% 
± 0.3%; Figure 3.7). Also application of lentiviral MMB without MF and US targeting did 
not enhance gene transfer substantially. Interestingly, even if US was applied in 
combination with lentiviral MMB no noteworthy increase in transduction efficiency was 
detected either. In contrast, lentiviral MMB with MF exposure resulted in a strong increase 
in transduction efficiency of both, SO-Mag MMB and PEI-Mag MMB coupled to GFP LV 
(26.0% ± 2.9% and 14.9% ± 2.3%, respectively; *p≤0.05, n=4). Importantly, a cumulative 
effect of combined MF and US exposure in addition to lentiviral MMB application on 
transduction efficiency could be observed for both MMB types (32.0% ± 0.8% and 23.0% 
± 3.0%, respectively; *p≤0.05, n=4). However, if comparing the transduction efficiencies 
of fully targeted lentiviral SO-Mag and PEI-Mag MMB with each other, SO-Mag MMB 
yielded an approximately 25% higher gene transfer (*p≤0.05, n=4). 
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Figure 3.7. Determination of transduction efficiencies of SO-Mag and PEI-Mag MMB as well 
as the single methodical parameters on endothelial cells under static conditions. 
(a) Full gene transfer efficiency could only be achieved by completely targeting the lentiviral 
MMB with MF and US. The omission of MF or US from the procedure resulted in significant 
reduction of GFP positive cells. In direct comparison, lentiviral SO-Mag MMB exhibited enhanced 
transduction capacity compared to lentiviral PEI-Mag MMB, with full targeting, respectively. 
*p≤0.05, n=4 in duplicates, 1-way ANOVA. (b) Representative fluorescence images of GFP 
expression in cells. Lower panels: representative transmission light pictures showing that the 
endothelial cell layers remained intact after incubation with lentivirus alone as well as US and MF 
targeting of lentiviral MMB. Scale bar indicates 500 µm. 
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3.1.9 Gene transfer efficiency of lentiviral MMB under flow conditions in vitro 
 
To evaluate the performance of the lentivirus-MMB complexes under flow conditions, 
endothelial cells cultured in channel slides were perfused with MMB complexed to 
lentivirus containing a luciferase reporter gene (veffLuc LV) and targeted by simultaneous 
application of MF and US. As seen in Figure 3.8.a, detected luciferase activity strongly co-
localized with the area of MNP accumulation, perceptible as brownish sediments. The 
lentiviral MMB-mediated gene transfer under a shear rate of 1 dyn/cm
2
 resulted in a strong 
and local luciferase expression regardless of the MNP type used. Under increased shear 
rates of 5 and 7.5 dyn/cm², the lentiviral SO-Mag MMB mediated transgene expression 
remained high. In contrast, lentiviral PEI-Mag MMB showed reduced transduction 
efficiencies under these enhanced shear conditions (Figure 3.8.b; *p≤0.05, **p≤0.01, n=4). 
As the SO-Mag MMB were repeatedly found to possess functional advantages under static 
as well as under flow conditions compared to PEI-Mag MMB, only the former were used 
in further experiments. 
In Section 3.1.8 it was demonstrated that the targeting of lentiviral MMB by MF and US 
under static conditions is essential to allow for maximal gene delivery (see Figure 3.7). To 
assess if this is also the case under flow conditions, we omitted either MF or US from the 
procedure while perfusing the lentiviral MMB with shear rates of 1 and 7.5 dyn/cm². As 
can be seen in Figure 3.8.c, luciferase expression was significantly decreased if MF 
exposure was omitted from the procedure compared to full treatment (**p≤0.01, n=4). 
Importantly, if only US without MF exposure was applied, transgene expression was 
minimal, emphasizing the importance of magnetic attraction under flow conditions for 
successful gene delivery (**p≤0.01, n=4). 
To verify the advantage of fully assembled lentiviral MMB over sole lentivirus-MNP 
complexes, we assessed the luciferase activities resulting from perfusion and targeting of 
these two solutions under shear rates of 1 and 7.5 dyn/cm² (SO-Mag MNP and MMB). As 
expected, application of lentivirus-MNP complexes resulted in significantly reduced gene 
transfer efficiency under both shear rates compared to lentiviral MMB application (Figure 
3.8.d; *p≤0.05, **p≤0.01, n=4). 
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Figure 3.8. Transduction efficiency of SO-Mag and PEI-Mag MMB under different shear 
rates and contribution of single method parameters to gene transfer efficiency under flow 
conditions. 
To study the performance of lentiviral MMB under flow conditions, HUVEC were cultured in flow 
channels and MMB were targeted by US and MF under constant perfusion with different shear 
rates. (a) MNP released from MMB mainly sedimented in the area of MF application. The resulting 
luciferase activity (detected 72 h after transduction) strongly co-localized with these MNP 
sediments. n=3. (b) Gene targeting efficiencies of lentiviral SO-Mag and PEI-Mag MMB with 
simultaneous MF and US application were similar under low shear of 1 dyn/cm². However, when 
increasing the shear (5 and 7.5 dyn/cm²) transduction efficiency of PEI-Mag MMB was strongly 
reduced while SO-Mag MMB delivered the genetic material with constant efficiency. *p≤0.05, 
**p≤0.01, n=4, 1-way ANOVA. (c) Gene transfer efficiency of SO-Mag MMB was significantly 
diminished if either MF or US were omitted from the targeting procedure independent from the 
applied shear rate (1 or 7.5 dyn/cm²). **p≤0.01, n=4, 1-way ANOVA. (d) The use of fully 
assembles MMB is essential for efficient gene delivery as targeting of sole lentiviral SO-Mag MNP 
did only yield weak luciferase expression. **p≤0.01, n=4, 1-way ANOVA. 
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3.2 Targeted gene expression in the aortic endothelium ex vivo using lentiviral 
SO-Mag MMB 
 
3.2.1 Localized GFP expression by targeting lentiviral SO-Mag MMB to the 
endothelium in mouse aortas 
 
As the lentiviral SO-Mag MMB were capable to achieve a local gene delivery under flow 
in vitro, we were furthermore interested to test their functionality ex vivo in isolated mouse 
aortas. To create conditions similar to in vivo conditions, we carried out the MMB 
targeting procedure under flow conditions using the recirculation setting as depicted in 
Section 2.1.16. Depending on the aortic diameter, a shear rate of around 7-8 dyn/cm
2
 was 
applied. GFP LV-SO-Mag MMB were targeted at the central section of the aorta by 
application of MF and US. The resulting GFP expression was essentially localized in the 
region of MF and US application, as visualized by fluorescence microscopy of the whole 
aorta 72 h after transduction (Figure 3.9.a; n=3). In aortas without MF and US targeting no 
transgene expression could be detected. Specific targeting of the endothelial cell layer was 
verified by PECAM-1 co-staining of GFP expressing cells in cross sections of the treated 
aortas (Figure 3.9.b; n=3). GFP expression was thereby uniquely found in endothelial cells 
and not in other cell types, such as vascular smooth muscle cells. 
 
Figure 3.9. Targeted delivery of GFP LV to aortic endothelium using SO-Mag MMB. 
(a) GFP LV complexed to SO-Mag MMB was locally delivered to mouse aortas (left panels) as 
visualized by fluorescence microscopy of the whole aortas. n=3. In contrast, aortas which were 
perfused with lentiviral MMB without targeting completely lacked transgene expression (right 
panels). The arrow indicates the site of MF and US application. Scale bar indicates 1 mm. (b) GFP 
expression was specifically found in aortic endothelial cells which were co-stained with the 
endothelial cell marker PECAM-1. Scale bar indicates 10 µm. n=3. 
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3.2.2 Targeted over-expression of VEGF in aortic endothelium for the enhancement of 
angiogenic responses 
 
To assess if the SO-Mag MMB mediated gene transfer is indeed capable to achieve 
functional alterations in the vascular endothelium, we applied a lentiviral construct 
harbouring an over-expression cassette for human vascular endothelial growth factor 
(VEGF). VEGF is a growth factor produced and secreted by different cells types upon 
stimulation by i.e. hypoxia. Upon binding of VEGF to VEGF receptors on endothelial cells 
angiogenic responses are elicited. To achieve over-expression in aortic endothelium, 
VEGF LV was complexed to SO-Mag MMB and targeted as described in Section 2.1.16. 
As control, aortas treated with GFP LV-SO-Mag MMB were prepared. Indeed, VEGF LV-
treated aortas expressed significantly higher levels of VEGF compared to GFP control 
aortas, as detected by qRT-PCR (Figure 3.10.a; **p≤0.01, n=5). Thereupon, it was 
assessed if this VEGF over-expression in endothelial cells also results in enhanced VEGF 
secretion and subsequent stimulation of vessel sprouting. Levels of secreted VEGF 
detected in medium supernatants 72 h after transduction were indeed significantly higher 
compared to levels in medium of GFP control aortas (Figure 3.10.b; **p≤0.01, n=5). In 
accordance with this, VEGF-transduced aortas generated significantly more sprouting tips 
resulting in a larger vascularization area compared to controls, as assessed by the aortic 
ring sprouting assay (Figure 3.10.c-e; *p≤0.05, n=3). 
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Figure 3.10. SO-Mag MMB mediated over-expression of VEGF in aortic endothelium results 
in enhanced angiogenic responses. 
(a) Successful over-expression of VEGF in isolated aortas achieved by SO-Mag MMB mediated 
transduction was detected by qRT-PCR with GFP-treated aortas as negative control. **p≤0.01, 
n=5, t-test. (b) VEGF expression in aortas resulted in 6-fold higher levels of secreted VEGF into 
the medium compared to levels secreted by GFP control aortas. **p≤0.01, n=5, t-test. (c) Strong 
angiogenic activation was observed in VEGF over-expressing aortic rings resulting in significantly 
higher numbers of sprouting tips and a larger vascularized area compared to rings from GFP 
control aortas. Scale bar indicates 200 µm. *p≤0.05, n=3 aortas with 6-8 rings each, 1-way 
ANOVA. 
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3.2.3 Functional analysis of SHP-2’s role during insulin resistance ex vivo 
 
3.2.3.1 Chronic exposure of endothelial cells to high insulin and glucose concentrations 
induces insulin resistance and a pro-inflammatory phenotype 
 
The successful targeted expression of VEGF in aortic endothelium clearly demonstrated 
that the SO-Mag MMB technique has the potential to deliver therapeutic genes at an 
intended site of a vessel resulting in physiological responses. Based on that, we were 
furthermore interested to study a new potential target in endothelial inflammation under 
insulin resistant conditions, the protein tyrosine phosphatase SHP-2, with the objective to 
verify our in vitro findings ex vivo using the lentiviral MMB technique. 
To study the inflammatory phenotype of endothelial cells under diabetic conditions, we 
generated insulin resistant endothelial cells by treatment with high insulin (100 nM) and 
glucose (15 mM) concentrations (high insulin/glucose: HIG) for 24 h or 48 h. Under such 
conditions, defective activation of central insulin-induced signaling molecules, such as 
PI3K and AKT, has been observed 
92, 93
. In accordance with this, cells kept under HIG 
conditions displayed strongly diminished AKT activation in response to short term (5 min) 
stimulation with 1 nM insulin (Figure 3.11.a; *p≤0.05, n=3). To assess the degree of 
endothelial inflammation, surface expression of the adhesion molecules ICAM-1 and 
VCAM-1 was detected by flow cytometry. Both adhesion molecules were strongly 
expressed on insulin resistant cells with highest expression levels after 48 h of HIG 
treatment (Figure 3.11.b; *p≤0.05, n=4-6). 
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Figure 3.11. Insulin resistant endothelial cells feature a strong inflammatory phenotype. 
(a) Short term stimulation of endothelial cells with 1 nm Insulin for 5 min strongly induced AKT 
activation. Upon chronic exposure of cells to HIG for 24 h and 48 h this activation of AKT was 
absent, as assessed by western blot. Total AKT levels remained unchanged under the different 
conditions. Graph shows quantification of pAKT band intensities normalized to β-actin. *p≤0.05, 
n=3, 1-way ANOVA. (b) ICAM-1 and VCAM-1 surface expression on endothelial cells 
significantly increased under chronic HIG conditions. *p≤0.05 vs. non stimulated cells, n=4-6 in 
duplicates, 1-way ANOVA. 
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3.2.3.2 SHP-2 phosphatase activity is diminished under insulin resistance in endothelial 
cells 
 
To assess if SHP-2 is involved in endothelial inflammatory signaling induced during 
insulin resistance, its phosphatase activity was detected. Therefore, SHP-2 protein was 
immunoprecipitated and incubated in a pNPP substrate solution. Interestingly, basal 
phosphatase activity of SHP-2 under control conditions could be detected (Figure 3.12.a). 
By incubation of the precipitated SHP-2 with the phosphatase inhibitor Na3VO4 (25 mM; 
*p≤0.05, n=4) a significant reduction in enzymatic activity of SHP-2 by around 50% was 
detected. This effect was reproduced by incubation with the specific SHP-2 inhibitor PtpI 
IV (2 µM; *p≤0.05, n=4). As can be seen in Figure 3.12.b, chronic insulin resistance (24 h 
HIG) resulted in a reduction of basal phosphatase activity similar to the effects seen with 
the pharmacological inhibitors (**p≤0.01, n=4). Importantly, the total protein levels of 
SHP-2 remained constant under HIG treatment (Figure 3.12.c; n=4). 
 
 
 
Figure 3.12. Detection of SHP-2 activity under basal and insulin resistant conditions. 
(a) SHP-2 exhibits basal phosphatase activity under normal conditions in endothelial cells, which 
was significantly reduced upon inhibition with the general phosphatase inhibitor Na3VO4 (25 mM) 
or the specific SHP-2 inhibitor PtpI IV (2 µM). *p≤0.05, n=4, 1-way ANOVA. (b) Upon 24 h HIG 
treatment, SHP-2 exhibits a strongly diminished phosphatase activity. **p≤0.01, n=4, t-test. (c) 
SHP-2 protein expression did not change under chronic insulin resistance as assessed by western 
blot. Graph shows quantitative analysis of SHP-2 band intensities normalized to β-actin. n=4, 1-
way ANOVA. 
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3.2.3.3 The phosphatase activity of SHP-2 negatively regulates endothelial adhesion 
molecule expression under insulin resistance 
 
To further analyse the impact of SHP-2’s phosphatase activity on inflammatory responses 
triggered by HIG treatment, two opposite enzyme mutants of SHP-2 (SHP-2 CS: dominant 
negative; SHP-2 E76A: constitutively active) were introduced to endothelial cells by 
lentiviral transduction. As control, cells over-expressing the wild type (WT) form of SHP-2 
were always measured alongside. First of all, the actual activity state of the three SHP-2 
proteins under basal conditions was checked. Therefore, proteins were precipitated from 
full lysates with an antibody recognizing the Myc-Tag sequence joined to the SHP-2 
sequences. Isolated proteins were then exposed to the pNPP assay. As anticipated, the 
SHP-2 CS mutant showed reduced phosphatase activity compared to the SHP-2 WT 
protein (Figure 3.13.a; *p≤0.05, n=3). In contrast to this, the activity of SHP-2 E76A was 
enhanced compared to SHP-2 WT (*p≤0.05, n=3). After verifying the functional 
phenotype of the SHP-2 enzyme variants, their effects under insulin resistant conditions in 
endothelial cells were assessed. As shown in Figure 3.13.b and d, over-expression of 
dominant negative SHP-2 CS led to significantly enhanced surface expression of ICAM-1 
and VCAM-1 after 24 h and 48 h HIG treatment compared to SHP-2 WT cells (*p≤0.05, 
**p≤0.01, n=6). In contrast to that, over-expression of the SHP-2 E76A mutant completely 
prevented adhesion molecule upregulation at both time points (*p≤0.05, **p≤0.01, n=6). 
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Figure 3.13. Analysis of SHP-2’s role during insulin resistance by over-expression of the SHP-
2 enzyme variants SHP-2 CS and E76A in endothelial cells. 
(a) The two enzyme mutants of SHP-2 exhibited reduced (SHP-2 CS) or enhanced (SHP-2 E76A) 
phosphatase activity compared to SHP-2 WT. *p≤0.05, n=3, 1-way ANOVA. (b) and (c) Insulin 
resistant cells (24 h and 48 h HIG) transduced with SHP-2 CS exhibited significantly enhanced 
surface levels of ICAM-1 and VCAM-1 compared to SHP-2 WT cells. In contrast, cells over-
expressing SHP-2 E76A showed reduced levels of these surface adhesion molecules. *p≤0.05, 
**p≤0.01, n=6, 1-way ANOVA. 
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3.2.3.4 Lentiviral SO-Mag MMB mediated expression of constitutively active SHP-2 represses 
the pro-adhesive switch in vascular endothelium ex vivo. 
 
To investigate if a targeted SO-Mag MMB assisted lentiviral gene delivery of the functional 
SHP-2 mutants is capable to modulate the pro-adhesive phenotype in insulin resistant 
endothelial cells, we applied this technique to isolated vessels. Therefore, the endothelium of 
mouse aortas was targeted under flow using SO-Mag MMB coupled to the respective lentiviral 
SHP-2 constructs (WT, CS or E76A) by simultaneous application of a MF and US as depicted 
in Section 2.1.16. Under insulin resistant conditions, increased ICAM-1 and VCAM-1 mRNA 
expression levels were detected in vessels expressing SHP-2 WT (Figure 3.14; *p≤0.05, n=3). 
In accordance with the effects observed in vitro, over-expression of SHP-2 CS significantly 
further increased ICAM-1 and VCAM-1 expression in aortas induced by chronic HIG 
treatment compared to SHP-2 WT expressing vessels (*p≤0.05, n=3). Importantly, over-
expression of SHP-2 E76A in vascular endothelial cells ex vivo completely prevented the 
induction of adhesion molecule expression seen under insulin resistance (*p≤0.05, n=3). 
 
 
 
 
Figure 3.14. SO-Mag MMB mediated expression of the enzymatic SHP-2 mutants (CS and 
E76A) to aortic endothelium substantially modulates the expression of adhesion molecules 
under insulin resistance. 
(a) and (b) Upon HIG treatment, mRNA expression of ICAM-1 and VCAM-1 was strongly 
induced in SHP-2 WT expressing aortas compared to non stimulated WT aortas. This induced 
adhesion molecule expression was significantly further enhanced in aortas expressing dominant 
negative SHP-2 (CS). In SHP-2 E76A expressing aortas, in contrast, adhesion molecule mRNA 
levels were similar to levels detected in non stimulated aortas. *p≤0.05, n=3, 1-way ANOVA. 
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3.3 Targeted gene delivery in vivo using the lentiviral SO-Mag MMB technique 
 
Since the lentiviral SO-Mag MMB technique has been shown to yield a significantly 
improved gene delivery in vitro as well as ex vivo, the next step to take was its application 
in vivo. However, the successful intravascular application of a gene carrier system in a 
whole organism strongly depends on its capacity to withstand several challenging 
conditions. To test the functionality of the SO-Mag MMB technique to specifically deliver 
the complexed lentiviruses to a desired vascular bed, the murine dorsal skinfold chamber 
(DSFC) model was used (for details see Sections 2.3.3 - 2.3.5). 
 
 
3.3.1 Biodistribution of MNP after intravascular application of lentiviral MMB 
 
If an injected nanomaterial is accumulated, biotransformed or degraded within an organism 
strongly depends on different physico-chemical and biological properties such as size, 
surface charge and core material. In case of the MMB, two components have to be 
considered for biocompatibility: the phospholipids DPPE and DPPC and the iron-oxide 
MNP. As DPPE and DPPC are both found in biological membranes, their in vivo 
application can be considered as unproblematic. The contained MNP, however, are foreign 
components. Therefore, the fate of the applied MNP was analyzed by magnetic particle 
spectroscopy (MPS). Importantly, this method specifically detects non-heme iron, thereby 
allowing for distinction of MNP-derived (exogenous) iron from endogenous iron contained 
in haemoglobin or ferritin. MPS was performed with homogenates of the main organs 
(heart, lung, liver, kidney, spleen, brain), which were isolated from mice 1 h as well as 96 
h after lentiviral SO-Mag MMB treatment. As shown in Figure 3.15, high amounts of 
exogenous iron were detected 1 h after treatment in all analyzed organs (n=4-5). The 
highest iron accumulation was thereby found in the liver (41.3% ± 9.4% of applied dose 
(o.a.d.)) followed by lung (19.1% ± 4.0% o.a.d.) and spleen (8.4% ± 2.0% o.a.d.). In the 
remaining organs (heart, kidney and brain) 4-5% o.a.d. were detected, respectively. The 
remaining 20-25% of applied MNP were probably taken up by organs and body 
compartments which have not been analyzed here. Surprisingly, only traces (between 0.1-
0.3% o.a.d.) of MNP-derived iron could be detected in all of the analyzed organs 96 h after 
treatment. 
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Figure 3.15. Systemic distribution of exogenous iron 1 h and 96 h after treatment. 
1 h after intra-aterial injection of SO-Mag MMB, more than 60% of the MNP were detected in liver 
and lung. However, 96 h after treatment, only traces of exogenous iron remained in the analyzed 
organs. n=4-5. 
 
 
 
3.3.2 Detection of residual lentiviral particles after in vivo application 
 
The lentiviruses used in this study were chosen due to their highly effective gene transfer 
as well as the resulting stable transgene expression in targeted cells. Importantly, only 
recombinant third-generation lentiviruses incapable to replicate after infection were used 
for all experiments. However, lentiviral particles which did not enter cells or have not been 
eliminated after treatment, represent a hazardous risk for the environment. To analyse 
potential sources of contamination of residual lentiviral particles, p24 core protein, a 
component of the lentiviral capsid, was detected in plasma, saliva, faeces, urine and smears 
from the skin area of the catheter surgery (injection site) sampled 48 h after lentiviral 
MMB treatment. As positive control a sample containing 2*10
5
 VP was measured. Except 
for the positive control, no remaining lentiviral particles were detected in the different 
samples indicating the complete uptake or clearance after systemic injection (Figure 3.16). 
Additionally, the absence of p24 core protein in the smear sample taken from the injection 
site proves that the lentivirus application via the Arteria carotis catheter represents a clean 
procedure without contamination risk. 
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Figure 3.16. Detection of p24 core protein in different body fluids and smears of lentiviral 
MMB injected animals. 
No residual lentiviral particles were detected in body fluids (plasma and saliva), excreta (faeces and 
urine) or injection area smears (throat skin) collected from mice 48 h after treatment as assessed by 
a p24 core protein ELISA (a) or direct application to HUVEC and fluorescence microscopy (b) 
(n=4 animals). In contrast, a strong signal was detected in the positive control sample containing 
2*10
5 
VP. 
 
 
 
3.3.3 Localized delivery of lentiviral vectors to the dorsal skin of mice by SO-Mag 
MMB targeting 
 
The intravascular application of genetic vectors is mainly limited by its lack of efficiency 
and site-specificity. The application of lentivirus coated SO-Mag MMB has shown 
promising results in the former presented in vitro and ex vivo experiments. In vivo, arterial 
injection of MMB via the Arteria carotis has been shown to be effective for targeted gene 
delivery of pDNA to the dorsal skin of mice 
40
. Therefore, the experimental setting for in 
vivo gene transfer using lentiviral MMB was adopted from this former study (for detailed 
settings see Figure 2.6). To allow for systemic analysis of transgene expression, the 
luciferase lentivirus was chosen. Eight days after lentiviral MMB targeting in vivo, mice 
showed a strong and local bioluminescence signal at the area of MF and US exposure 
indicating successful delivery of the luciferase expressing lentivirus via SO-Mag MMB 
targeting (Figure 3.17.a and b, right image and graph; n=3). Lentiviral MMB injection 
without MF and US targeting, in contrast, did not result in a luciferase activity signal in the 
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DSFC (Figure 3.17.a and b, left image and graph; n=3). Successful targeting was 
furthermore verified by quantitative analysis of absolute genome copy numbers of proviral 
DNA, which was significant higher in animals with MF and US targeting (Figure 3.17.c). 
However, the spleen and lung were identified as second expression sites in animals of both 
groups (Figure 3.17.d). Interestingly, whereas lentiviral MMB treatment without MF and 
US targeting caused strong transgene expression in the spleen and liver (Figure 3.17.d, 
upper images), lentiviral MMB treatment with MF and US targeting reduced the transgene 
expression in the liver (Figure 3.17.d, lower images). This finding was further confirmed 
by detecting the proviral genome copy numbers in liver homogenates. There, the livers of 
mice in which the lentiviral MMB were targeted to the dorsal skin exhibited significantly 
reduced proviral genome insertions compared to livers of mice without targeting (Figure 
3.17.e). In lung tissues, in contrast, genome copy numbers remained the same regardless if 
MMB targeting was performed or not (Figure 3.17.f). 
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Figure 3.17. SO-Mag MMB achieve targeted lentiviral delivery after systemic injection in 
vivo. 
(a) Representative bioluminescence images of the DSFC observation window in mice received 8 
days after Luc-MMB application. Upon magnetic and ultrasonic targeting of Luc-MMB to the 
DSFC window a strong and local luciferase expression could be detected (right image). In contrast 
to this, injection of Luc-MMB without targeting resulted in no detectable luciferase activity in the 
DSFC window area (left image). n=3 animals. (b) Quantitative measurements of pixel densities in 
DSFC windows of mice +/- MF and US targeting. n=3 animals. (c) Numbers of proviral DNA 
integrations in DSFC window tissue +/- MF and US targeting. *p≤0.05, n=3 animals, t-test. (d) 
Systemic distribution of luciferase expression in Luc-MMB treated mice was assessed by whole-
body bioluminescence measurements (left upper and lower images) as well as detection in isolated 
organs (right upper and lower images). Luciferase activity was detected in the spleen and liver in 
animals receiving lentiviral MMB without targeting (upper images), whereas non-specific 
transgene expression in mice receiving lentiviral MMB and targeting was mostly in the spleen 
(lower images). n=3. (e) Detection of proviral DNA integration numbers revealed that MF and US 
targeting to the DSFC reduces unspecific genome integrations in the liver. *p≤0.05, n=5 animals, t-
test. (f) In contrast, genome copy numbers in lungs of mice +/- MF and US targeting remained 
unchanged. *p≤0.05, n=5 animals, t-test 
Luc: Luciferase, MMB: Magnetic microbubbles, MF: Magnetic Field, US: Ultrasound, DSFC: 
dorsal skinfold chamber, TM: Transmission, BL: Bioluminescence. 
 
DISCUSSION | 72 
 
4 Discussion 
 
This thesis describes the establishment and verification of an advanced vascular gene 
targeting approach, the lentiviral magnetic microbubble (MMB) technique. Here, 
ultrasonic microbubble-mediated delivery and magnetic nanoparticles (MNP)-assisted 
transport were combined with lentiviral gene delivery resulting in a potent gene transfer 
system eligible for functional in vitro and ex vivo studies as well as in vivo applications. 
Two types of MMB coated with different superparamagnetic iron-oxide nanoparticles (SO-
Mag and PEI-Mag MNP) were directly compared to evaluate their functional and 
biological performance. The superior SO-Mag MMB were then further applied to analyse 
the potential of the MMB technique to also achieve physiological responses by targeted 
lentiviral gene transfer to the endothelium in intact isolated vessels. Moreover, site-specific 
gene delivery by SO-Mag MMB-mediated lentiviral transduction in vivo was evaluated by 
using the dorsal skinfold chamber (DSFC) model in mice. 
 
 
4.1 Comparison of the newly established SO-Mag MMB with PEI-Mag MMB 
 
4.1.1 Physico-chemical characteristics 
 
The effectiveness of a gene carrier system is always the result of the successful cooperation 
of its single components. The different characteristics of the combined materials therefore 
substantially influence structural aspects such as size, charge and stability. The magnetic 
microbubbles (MMB) presented in this study feature a gas filled core encapsulated by a 
homogenous phospholipid-MNP shell. In former studies of us, microbubbles coated with 
PEI-Mag MNP were demonstrated to successfully bind and deliver genetic vectors, such as 
pDNA and lentiviruses to endothelial cells 
40, 41
. However, in a study from Mykhaylyk et 
al., a new type of silica-coated iron-oxide MNP, named SO-Mag MNP, were found to 
possess improved magnetic properties (e.g. 1.5-fold higher magnetic moment) compared to 
the former established PEI-Mag MNP 
84
. This finding was decisive for the establishment of 
new MMB containing SO-Mag MNP. To allow for an accurate evaluation of the SO-Mag 
MMB they were directly compared to PEI-Mag MMB. It has been shown that not every 
MNP type is adequately incorporated to the lipid shell of microbubbles 
40
. However, 
similar to PEI-Mag MNP, SO-Mag MNP evenly distribute in the lipid layer resulting in 
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floating and magnetic responsive MMB. With a mean diameter below 5 µm in 
combination with their flexible lipid shell the generated SO-Mag MMB showed positive 
characteristics for later in vivo applications, where the ability to freely pass through the 
smallest capillary beds determines the success and applicability of a gene transfer method. 
A further essential prerequisite for MMB to be suitable as vascular gene carrier is their 
ability to resist blood flow upon local MF exposure. MNP alone have been implemented as 
gene carriers in many in vitro and in vivo studies by us 
32, 94, 95
 and other groups 
34, 36, 82
. 
This so called magnetofection method not only improved gene delivery to cultured cells 
under static and flow conditions but also reduced cytotoxicity due to the decrease in 
transfection duration 
32
. However, magnetofection after systemic administration in vivo, 
has proven to be difficult probably due to low magnetic moments of the single MNP, 
particle aggregation as well as rapid clearance from the circulation by interactions with 
immune cells and the glycocalix. The embedding of several MNP within the lipid 
monolayer of a MB has not only the advantage to reduce their biological clearance but also 
enormously increases the ability of site-specific targeting by withstanding the forces of 
blood flow in comparison to single MNP application. Indeed, a single MMB exhibited an 
about 2x10
5
-fold higher magnetic moment compared to the respective single MNP. 
Interestingly, twice the number of SO-Mag MNP were incorporated into the MMB 
compared to PEI-Mag MNP. This, in combination with the formerly mentioned higher 
magnetic moment of single SO-Mag MNP compared to PEI-Mag MNP, accounts for the 
enhanced magnetic velocity and magnetic moment observed with SO-Mag MMB. 
 
 
4.1.2 Lentivirus-binding properties 
 
Gene transfer efficiency and associated therapeutic success is substantially determined by 
the choice of the genetic vehicle with which a targeting system is combined. Lentiviruses 
represent ideal vectors for the delivery of therapeutic genes to vascular endothelial cells as 
they are capable to infect even slow or non dividing cells and enable permanent transgene 
expression due to stable genome integration 
5, 12
. However, in clinical gene therapy 
lentiviruses are currently only applied as vehicles for ex vivo transduction of autologous 
hematopoietic stem cells of patients with hematopoietic disorders 
14-16
. The major obstacles 
of systemic lentivirus application, such as immune activation and insufficient targeting, 
might be solved by combining lentiviral gene transfer with MMB-mediated targeting. The 
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association of negatively charged lentiviruses to MNP has been shown to be favoured if the 
MNP features a positive ζ potential thereby enabling electrostatic interactions. The here 
applied MNP featured opposite surface charges due to their respective coatings. While the 
PEI-Mag MNP exhibited a positive ζ potential of +55.4 mV, SO-Mag MNP possessed a 
negative surface charge of -33.7mV. Surprisingly, in this study, MMB coated with the 
negatively charged SO-Mag MNP were equally capable to bind the negatively charged 
lentiviruses (-8.8 mV) as were the positively charged PEI-Mag MNP. This is interesting as 
in a former study of us, it was demonstrated that MMB generated with negative palmitoyl 
dextran-coated MNP (PalD1-Mag4 and PalD2-Mag1) were not capable to efficiently bind 
lentiviral particles 
41
. However, in contrast to this study, the ζ potential of the PalD-Mag 
MMB has not been assessed leaving the question regarding the actual surface charge of 
these MMB open. The here generated new SO-Mag - MB complexes actually exhibited a 
positive ζ potential similar to that of the PEI-Mag MMB giving a plausible explanation for 
the good lentivirus-binding properties of both the MMB types. As the naked MB exhibited 
a ζ potential of +6.2 mV it seems likely that the negative silica-groups on the surface of the 
SO-Mag MNP were masked resulting in the positive cumulative charge of the SO-Mag 
MMB. This finding is particularly meaningful regarding future choices of new MNP, as 
they demonstrate our system to be partially independent of the surface charge of the MNP 
itself, which means that attention can rather be focussed on magnetic properties. 
Importantly, nearly the complete amount of lentivirus added to the MMB solutions (5*10
6
 
IP/ml) was bound by both the MMB types as demonstrated by magnetic separation of the 
lentiviral MMB from the bubble free supernatant and subsequent MF and US targeting to 
endothelial cell cultures. However, the concentrated lentiviral SO-Mag MMB achieved a 
significantly increased transduction rate of endothelial cells compared to PEI-Mag MMB. 
As the lentivirus loading of SO-Mag and PEI-Mag MMB was the same, this effect can 
only be based on the enhanced magnetic moment of SO-Mag MMB resulting in a more 
effective gene transfer. 
 
 
4.1.3 Cytotoxicity of the MMB technique 
 
Biocompatibility is the major criterion for the applicability of newly established 
nanomaterials and chemical components in biomedicine. The MNP and lipid components 
used in this study did not induce cytotoxicity in primary endothelial cells, known to be 
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rather sensitive to external stimuli. This emphasizes the safety of the MMB system 
important for later in vivo application. However, a reduction of cell viability by around 
20% was detected after US application. This cytotoxicity most probably results from the 
direct exposure of cultured cells to the ultrasonic waves given into the cell culture medium, 
which has also been observed in other studies applying a variety of US parameters 
96, 97
. 
Interestingly, this extent of cytotoxicity was constant regardless if lentiviral MMB were 
abundant or not indicating that the MMB sonication itself did not contribute to the 
observed cell toxicity. Importantly, neither in this nor in a former study of us 
40
, tissue 
damages, inflammatory responses or haemorrhages were observed in the dorsal skin in 
vivo upon application of US. This might be due to potential insulation effects exerted by 
surrounding fibers and tissue, which reduce the mechanic stress caused by US thereby 
maintaining cell integrity. 
 
 
4.1.4 In vitro performance under static and flow conditions 
 
First, to clearly demonstrate the supremacy of the MMB technique over sheer MNP-
mediated lentiviral gene delivery (magnetofection), both were tested on endothelial cells 
under flow conditions with full US and MF targeting. Despite the fact that magnetofection 
has been demonstrated to have advantages regarding gene transfer effectivity and rapidness 
in vitro 
34, 94
 it was proven to be much less effective under flow conditions compared to the 
lentivirus-MMB complexes. To further pursue the finding that SO-Mag MMB delivered 
their bound lentiviruses with significantly higher efficiency to endothelial cells than PEI-
Mag MMB, further in vitro targeting experiments under static as well as flow conditions 
were performed. Therefore, the single parameters of the MMB technique (MMB, US and 
MF) were tested for their respective contribution to the over-all transduction efficiency of 
the method. Magnetic targeting of the MMB was found to be the most critical parameter 
accounting for around 70% or 60% of the complete transduction efficiency under static or 
flow conditions, respectively. Importantly, the combination of magnetic targeting with 
MMB sonication by US further increased the gene transfer. The importance of US 
application in addition to MF exposure for successful in vivo transduction has been shown 
before with pDNA-coated MMB 
40
. The enhancing effect on gene transfer by sonication 
might be explained by the cooperation of two events triggered by US application: The 
release of the lentiviral cargo upon MMB destruction 
98
 and the simultaneous induction of 
DISCUSSION | 76 
 
pores on cell membranes going along with enhanced cellular permeability (sonoporation) 
and endocytic activity 
25, 99
. Therefore, magnetic accumulation and ultrasonic destruction 
of the lentiviral MMB may be seen as equally important for the success of the MMB 
technique in vivo. Importantly, upon magnetic and ultrasonic targeting, SO-Mag MMB 
delivered the bound lentiviruses with significantly higher efficiency to endothelial cell 
cultures than PEI-Mag MMB. This is in accordance with the previously assessed magnetic 
properties of the MMB types, where SO-Mag MMB were shown to possess a three-fold 
higher magnetic moment than PEI-Mag MMB. Considering these superior characteristics 
of the SO-Mag MMB over PEI-Mag MMB, only the former were further applied for the 
successive experiments of this study. 
 
 
4.1.5 Analysis of the endocytic mechanism responsible for MMB-mediated 
transduction 
 
There are numerous studies addressing the effects of microbubble sonication on cells and 
the associated enhanced gene delivery seen under these conditions. Sonoporation, the 
enhancement of permeability of cell membranes resulting from sublethal ultrasound 
exposure, accompanied by clathrin- or caveolae-dependent endocytosis are the most 
accepted explanations for these effects 
25, 100, 101
. The major difference between both these 
endocytic mechanisms is given by the fact that clathrin-mediated endocytosis is receptor-
dependent while caveolae-mediated processes occur independent from receptor signaling 
102
. Due to these molecular differences, both mechanisms can be selectively inhibited and 
therefore discriminated. As caveolae formation is substantially dependent on the 
abundance of adequate amounts of cholesterol, cholesterol depletion by Methyl-β-
cyclodextrins is an effective way to prevent this endocytic pathway 
86
. On the other hand, 
endocytosis induced by clathrin-recruitment has been shown to strongly depend on F-actin 
dynamics and can be inhibited by actin depolimerizing substances such as Cytochalasin B 
88
. A third possible pathway for viral particles to enter cells is pH-dependent phagosome-
lysosome fusion. Therefore, also phagosome-lysosome fusion was inhibited by pH 
neutralization using ammonium chloride 
87
. Using the full targeting settings in combination 
with the different inhibitors, we found transduction by lentiviral SO-Mag MMB to be 
mediated by caveolin-dependent endocytosis, potentially induced by sonication. Therefore, 
it might be hypothesized that the enhanced transduction efficiency of the MMB technique 
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is the result of magnetic approximation between lentiviral MMB and cells and subsequent 
sonication-dependent induction of caveolin-dependent endocytosis. However, due to the 
complexity of the whole targeting system the exact mechanism has to be reviewed in 
further studies. 
 
 
 
4.2 The lentiviral SO-Mag MMB technique as tool to modulate physiological 
processes in aortic endothelium ex vivo 
 
4.2.1 Verification of localized protein expression in aortic endothelium by MMB-
mediated transduction 
 
The intention to apply a gene therapy approach in vivo requires careful evaluation of its 
abilities to achieve efficient gene transfer not only under idealized cell culture conditions, 
but also under conditions which are similar to the actual complex in vivo environment. 
Aspects such as particular cell surface structures (e.g. cell junctions, glycocalix) as well as 
blood flow and blood components can substantially impair the accessibility of genetic 
vectors to the endothelial cell layer. Considering these factors, the newly established 
lentiviral SO-Mag MMB were tested for their transduction efficiency when applied to 
intact endothelial tissue as can be found in isolated mouse aortas. To furthermore approach 
in vivo conditions, MMB targeting was performed under flow with applied shear stress of 
7-8 dyn/cm
2
. Successful gene targeting to endothelial cells ex vivo could be visualized by 
the local expression of GFP in the transduced area and subsequent immunofluorescence 
staining. Importantly, no dissolution of the endothelial cell layer from the vessel wall could 
be observed in the aortic segments indicating good tolerance of the procedure. Moreover, 
our method did not reach deeper tissue, such as the vascular smooth muscle cell layer, 
proving its selectivity for endothelial gene transfer. This selectivity is desirable for many 
potential therapeutic applications intending endothelial gene manipulation. However, if 
targeting of deeper tissues from the luminal side is intended the current methodical settings 
need to be re-evaluated to assess gene transfer more precisely for different organs and 
tissues which exhibit heterogeneous endothelial phenotypes 
103
. The precise modulation of 
the applied ultrasonic pulse might be the key component in this regard. It must be said that 
neither the effects of blood and blood components nor the role of the glycocalix, a 
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carbohydate-rich layer covering native endothelium 
104
, were regarded in the here 
employed ex vivo experiments as these specific environmental factors are difficult to 
simulate ex vivo. These will be discussed later in this work in the context of the actual in 
vivo applications (Section 4.3). The subsequent ex vivo studies were performed to further 
validate the therapeutic value of the lentiviral MMB approach as well as elucidate 
molecular and functional relations in vascular endothelial cells. 
 
 
4.2.2 Induction of angiogenic responses by targeted over-expression of VEGF in 
isolated vessels 
 
The modulation of angiogenic responses in endothelial cells is one of the most commonly 
regarded aims in therapeutic research. Vascular endothelial growth factor (VEGF) has 
thereby evolved as promising target since it is the most potent angiogenic factor with 
unique actions on vascular endothelium 
53
. Depending on the pursued therapeutic purpose, 
genetic strategies aim at either promoting 
54, 55
 or inhibiting 
56
 angiogenesis by induction or 
inhibition of VEGF, respectively. Here, the applicability of the lentiviral SO-Mag MMB 
technique for physiological relevant gene transfer of human VEGF to aortic endothelial 
cells was to be evaluated. Upon lentivirus targeting, VEGF expression could be 
successfully detected on mRNA level which was reflected by the high levels of secreted 
VEGF detected in the medium supernatant of transduced aortas. Importantly, this constant 
secretion of VEGF from targeted endothelial cells indeed resulted in functional responses, 
namely strong pro-angiogenic behaviour. These results provide firm evidence for the 
relevance of the lentiviral MMB technique not only as scientific but also as therapeutic 
tool. Due to the central role of VEGF during angiogenic processes, VEGF-based therapies 
constitute very promising treatment strategies. However, the systemic application of drugs 
targeting VEGF is not feasible due to the severe complications this may cause. Especially 
the enhancement of VEGF activity in ischemic regions requires local treatment to prevent 
hypervascularization in unintended body areas. However, despite great scientific and 
clinical efforts, no effective VEGF-based targeting approach from the intravascular side 
has been successfully established so far 
65
. Even direct localized injections or catheter-
mediated approaches did not satisfy the expectations emerged after earlier animal studies 
55, 64
. Therefore, the advancement of the here presented gene carrier approach might be a 
valuable step towards successful tissue-specific angiogenic therapy. 
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4.2.3 Functional analysis of the phosphatase activity dependent role of SHP-2 during 
endothelial dysfunction in vitro and ex vivo 
 
4.2.3.1 Study of SHP-2’s role during insulin resistance-induced inflammation in primary 
endothelial cells 
 
The SH2 domain-containing protein tyrosine phosphatase-2 (SHP-2) has repeatedly been 
shown to play a role in inflammatory signaling and tissue responses 
66, 70, 105
. In endothelial 
cells, SHP-2 is an important regulator of angiogenic 
75, 76
 and inflammatory responses 
72, 77, 
78
. For instance, it was found to control adhesion molecule upregulation in endothelial cells 
induced by chronically high concentrations of insulin 
72
. These findings strongly indicate 
that SHP-2 may be an important player in the development of endothelial dysfunction, a 
major feature frequently found in patients with metabolic disorders such as diabetes 
mellitus 
106
. 
Insulin is a hormone essentially involved during metabolic homeostasis and 
microcirculatory vasoreaction 
107
. In endothelial cells, the PI3K and MAPK cascades have 
been elucidated as major opponent pathways responsible for insulin-dependent effects 
45
. 
While activation of PI3K/AKT downstream signaling has been shown to result in 
vasodilative actions due to enhanced NO production 
83, 84
, MAPK signaling was shown to 
increase the expression of pro-thrombotic and pro-inflammatory factors such as ET-1, PAI-
1 and adhesion molecules 
108, 109
. A mutual regulation of both these pathways has been 
suggested and is assumed to sustain the physiological state of the endothelium 
110
. Under 
insulin resistance, however, this balance is tilted due to reduced PI3K/AKT- and enhanced 
MAPK-dependent effects causing a pro-adhesive, pro-inflammatory and vasoconstrictive 
endothelial phenotype 
111
. Although a multiplicity of signaling molecules participating in 
these key pathways have been identified some gaps still remain. Interestingly, the tyrosine 
phosphatase SHP-2 has been demonstrated to play a role in both the PI3K and the MAPK 
pathway in different cell types regulating processes including apoptosis, proliferation, 
angiogenesis and inflammation 
66
. Therein, the three functional domains of SHP-2 (PTP, 
SH2 and pY domains) have been shown to enable distinct signal modulation depending on 
the applied stimulus 
63, 66-69
. However, so far, the role of SHP-2’s phosphatase domain for 
the development of insulin-resistant pro-inflammatory phenotype in endothelium has been 
investigated only insufficiently 
72
. Here, insulin-resistance of primary endothelial cells was 
successfully induced by chronic exposure to pathological concentrations of insulin and 
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glucose. The actual proof of this condition was provided by the characteristic incapacity of 
insulin-resistant endothelial cells to activate AKT upon low level insulin stimulation 
83, 84
 
as well as the enhanced surface expression levels of the adhesion molecules ICAM-1 and 
VCAM-1 also seen in patients with insulin resistance 
112
. In fact, this switch towards a pro-
inflammatory phenotype of the endothelium has been shown to be critically important for 
the recruitment of pro-inflammatory neutrophils and associated increased occurrence of 
cardiovascular events 
113
. Interestingly, our data revealed that insulin resistant cells 
exhibited a 30% reduction of the basal SHP-2 phosphatase activity seen in non insulin-
resistant cells. No time dependent increase of SHP-2 protein levels upon chronic insulin 
could be held responsible for this enhanced phosphatase activity. Therefore, SHP-2 
enzyme activity is probably reduced by posttranslational modifications of the active site 
cystein such as S-nitrosylation or oxidation. Both these mechanisms have been shown to 
result in reversible inhibition of SHP-2’s phosphatase activity 
69, 114, 115
. Which of these two 
mechanisms actually accounts for the SHP-2 inhibition observed here, however, remains to 
be determined. Furthermore, enhanced adhesion molecule expression was observed in cells 
expressing a dominant negative SHP-2 CS mutant while a constitutively active SHP-2 
E76A mutant prevented this pro-inflammatory switch. These findings are in direct contrast 
to the study of Giri et al., where SHP-2 activation and subsequent enhanced expression was 
shown to be responsible for the pro-inflammatory phenotype of endothelial cells 
chronically treated with high insulin concentrations 
72
. However, these discrepancies to the 
here presented results may be explained by different facts. Firstly, in contrast to Giri et al. 
who applied high insulin concentrations to induce insulin-resistance in endothelial cells, 
we used a glucose/insulin-double exposure model. Furthermore, it should be noted that for 
some of their studies Giri et al. used the pharmacological inhibitor NSC 87877, which is 
non-selective for SHP-2 and its closest family member SHP-1 
110
. Unlike their statement, 
SHP-1 is abundant in endothelial cells and has been demonstrated to influence hypoxic 
signaling 
116
, angiogenesis 
109
 and apoptosis 
117
. The use of NSC87877 to study SHP-2 
related effects is therefore not eligible as a substantial interferences due to simultaneous 
SHP-1 inhibition cannot be excluded. In contrast to that, we used a highly selective and 
therefore more reliable SHP-2 inhibitor (Ptp I IV) to assess the basal activity of SHP-2 in 
endothelial cells. The use of enzyme mutants further verified the anti-inflammatory role of 
SHP-2 under endothelial insulin resistance found with the Ptp I IV inhibitor. In the study of 
Giri et al., siRNA knock down of SHP-2 and over-expression of a SHP-2 tyrosine 
phosphorylation site mutant were applied to validate the effects seen with the NSC87877 
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inhibitor. However, a collective interpretation and comparison of the results gained with 
these three approaches (enzyme inhibition, protein knock down and adaptor mutation) is 
rather difficult as they concern different functional domains of SHP-2. 
 
 
4.2.3.2 Modulation of the inflammatory phenotype of insulin-resistant vascular 
endothelium by lentiviral MMB mediated over-expression of SHP-2 phosphatase 
mutants in ex vivo 
 
To further verify the previous described phosphatase-dependent effects of SHP-2 during 
insulin-resistance also in intact native endothelium, the lentiviral MMB technique was 
used. Therefore, the same SHP-2 phosphatase mutant constructs as have been used in the 
in vitro studies were delivered to the endothelial layer of isolated mouse aortas by 
application of MF and US. Remarkably, the resulting over-expression was found to induce 
the same expression pattern of adhesion molecules as was observed in primary endothelial 
cells. 
Our findings indicate that SHP-2 reactivation in insulin resistant endothelium, for example 
by SHP-2 E76A over-expression, has therapeutic potential for the treatment of endothelial 
inflammation in diabetic patients. Importantly, also in intact endothelium, expression of 
SHP-2 E76A strongly attenuated the upregulation of adhesion molecules under insulin 
resistant conditions again reassuring its strong anti-inflammatory potential. The completely 
opposed adhesion molecule pattern seen with the SHP-2 CS mutant emphasizes that the 
effects observed under these conditions indeed depend on SHP-2’s phosphatase activity. In 
summary, we were able to change a patho-physiological phenotype in intact vessels using 
the lentiviral MMB technique demonstrating the great potential of this technique for gene 
therapy. 
A further application of functional SHP-2 mutants in combination with the lentiviral MMB 
technique might be found in the area of angiogenic therapy. In a former study of us, SHP-2 
phosphatase activity was demonstrated to be crucial for endothelial cell survival and vessel 
formation in vivo 
76
. Thus, localized delivery and subsequent expression of SHP-2 E76A 
may be desired in the field of ischemic revascularization, while SHP-2 CS expression 
could hamper vascularisation and growth of tumours. Additionally, SHP-2 activity-related 
gene therapy could be useful in diabetic patients featuring insulin resistance, which are 
known to possess reduced wound healing capacity 
49
. The application spectrum of the LV-
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MMB method presented in this study are miscellaneous and go far beyond the here 
described delivery of functional SHP-2 mutants. However, by demonstrating its capacity to 
achieve efficient and physiological relevant gene transfer in whole vessels, a foundation 
for following in vivo studies was laid. 
 
 
 
4.3 Vascular gene delivery of lentiviral vectors by magnetic and ultrasonic 
targeting of SO-Mag MMB in vivo 
 
The methodical conjunction of microbubble mediated transport, magnetic accumulation 
and ultrasonic delivery is a promising concept for vascular gene delivery. The MMB 
technique presented in this study constitutes the realization of such a multimodal targeting 
approach. In two former studies of us, the PEI-Mag MMB could be shown to complex and 
deliver pDNA 
40
 and lentiviruses 
41
 to endothelial cells, whereby the actual in vivo 
applicability has only been demonstrated with pDNA-coupled MMB. However, vascular 
gene delivery using naked DNA vectors is known to result in rather low gene expression 
and has accordingly low physiological relevance. The combination of MMB with more 
effective genetic vectors, such as lentiviruses, was therefore an essential step for the 
advancement of the method towards its therapeutically relevant in vivo application. As 
described before, the newly established SO-Mag MMB were shown to possess functional 
advantages compared to formerly used PEI-Mag MMB allowing for effective gene transfer 
even to intact aortic endothelium. If the supremacy of lentiviral SO-Mag MMB persists 
under complex in vivo conditions was tested using the DSFC model in mice. By 
simultaneous MF and US application, arterial delivered lentiviral MMB were targeted to 
the microcirculatory bed of the dorsal skin. Indeed, local reporter gene expression 
(luciferase) in the dorsal skin was detected 8 days after the targeting procedure. In dorsal 
skins of mice without targeting, in contrast, reporter gene expression was completely 
absent highlighting the importance of MF and US application. The detection of absolute 
proviral genome insertions in the DSFC tissue confirmed this finding as lentiviral MMB 
targeting indeed resulted in significantly more proviral genome copies than no targeting. 
Except for the previous mentioned pDNA-MMB study 
40
, no comparable experimental 
strategy enabling this local delivery of genetic vectors from the systemic circulation by 
magnetic and ultrasonic targeting has been established so far. In other studies, relevant 
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vascular gene expression has only been achieved by local catheter-mediated delivery or 
direct tissue injection 
6, 55, 64
. Furthermore, in advanced clinical studies, these methods 
mostly did not result in beneficial physiological effects most probably due to too low gene 
transfer rates 
118
. Whether the lentiviral MMB technique indeed is capable to outperform 
these other methods in terms of gene expression and resulting physiological effects 
remains to be evaluated. 
However, although lentiviral transduction could be successfully directed to the dorsal skin, 
unintended expression in other organs was also detected. Off-target reporter gene 
expression was thereby concentrated to the spleen and liver of mice. However, a reduced 
unspecific expression and proviral genome copy number in liver tissue of mice with US 
and MF targeting compared to mice without MMB targeting was detected. This finding 
may be accredited to a reduction of freely circulating MMB du to the local capturing at the 
site of MF and US application resulting in less unspecific liver expression. Interestingly, 
no luciferase activity could be detected in one of the other analyzed organs, such as lung or 
kidneys. The observed expression patterns after lentiviral MMB application mostly 
conform to results of others investigating the biodistribution of systemically injected viral 
particles 
11, 119, 120
. However, in contrast to our study, they constantly found transgene 
expression to be higher in liver than in spleen. This is probably due to the chosen route of 
application, which was intra venous and intra peritoneal. Intra arterial injection of 
lentiviruses, as conducted here, may enhance the splenic off-target expression, as the 
MMB pass the spleen before passing the liver. Another hypothesis might be that the 
complexation of lentiviruses with MMB enhances the uptake of lentiviral particles by the 
spleen due to their erythrocyte-like structural features. However, as the main proportion of 
MNP shortly (1 h) after MMB administration was found to be located in liver and lung, an 
enhanced uptake of whole lentivirus-MMB complexes by the spleen seems rather unlikely. 
Importantly, the further analysis of MNP distribution four days after MMB injection 
clearly revealed a fast and nearly complete clearance of administered MNP from the body. 
Whether this clearance occurs via hepatic or renal excretion or via biotransformation of the 
iron-oxide nanoparticles and subsequent uptake to the endogenous iron metabolism 
remains to be determined. This fast elimination as well as the low MNP cytotoxicity 
attested in vitro strongly indicates the MMB technique as a biocompatible gene delivery 
approach. Moreover, with an iron dose of 1 µg Fe/g body weight, the here presented MMB 
technique requires about 100-1000-fold less MNP amount than have been used by other 
groups aiming in vivo gene targeting by MNP 
121
. In a study investigating the liver toxicity 
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in mice after acute injection of iron-dextran, no notable increase in lipid peroxidation was 
detected up to a dose of 50 µg/g body weight 
122
. However, to estimate the risk of an iron 
overload and associated severe organ failure resulting from enhanced ROS production, 
more specific studies regarding hepatic iron concentrations and oxidative stress upon 
MMB injection need to be done. In healthy individuals, hepatic iron concentrations are 
approximately 36 µmol/g liver dry weight (2 mg/g). Hepatic iron overload and accordingly 
organ damages are estimated to occur at a threshold of > 80 µmol/g liver dry weight (4 
mg/g) 
123
. However, these levels may only be reached upon chronic administration of 
exogenous iron, as it is necessary in patients requiring long-term blood transfusions. 
 
 
 
4.4 Therapeutic potential and future perspectives 
 
In most cases, long-term treatment of cardiovascular diseases requires repeated and 
continuous drug intake by the patient to sustain the therapeutic drug level. The appearance 
of associated side effects not only results from systemic drug application but can also be 
assigned to unspecific off-target actions of the drug. Furthermore, systemic delivery 
oftentimes impedes the actual beneficial effects of a therapeutic agent as the necessary 
concentrations at the site of intervention cannot be reached. 
The elucidation of molecular and genetic causes of cardiovascular diseases progresses 
rapidly and opens new possibilities for more specific and personalized treatment strategies. 
In this regard, gene therapeutic approaches gain more and more attention. However, their 
application is still hampered due to the lack of efficient and targetable gene delivery 
methods. The here presented lentiviral MMB technique represents a promising step 
towards such a gene targeting approach for the vascular system. The ability to direct and 
accumulate lentiviral vectors, which are known for their efficient gene transfer and stable 
transgene expression, may allow for the specific over-expression, knock out, or 
replacement of virtually any gene. As the method currently is restricted to endothelial gene 
therapy, molecular targets involved in endothelial specific pathological processes are of 
particular interest. 
One highly interesting therapeutic molecule in this context, the vascular endothelial growth 
factor (VEGF), has been regarded in this work. The research field of VEGF-based 
therapies is highly active due to its central relevance in angiogenesis-related disorders. The 
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treatment of ischemic diseases, such as myocardial infarction and limb ischemia, as well as 
diseases associating a hyperangiogenic vasculature, such as tumours, might be 
revolutionized by the application of lentiviral MMB gene delivery. That the MMB in 
principle can be applied for VEGF-based therapy has been proven in this study where the 
local transduction of aortic endothelial cells indeed resulted in angiogenic responses. 
Reversely, the delivery of VEGF knock out constructs to tumour vasculature by the MMB 
technique might be especially valuable to restrict tumour progression and metastasis. Apart 
from this, the further spectrum of application is huge and includes localized modifications 
of relevant gene expression in for example atherosclerotic lesions as well as vascular 
regions prone to thrombotic and inflammatory complications. 
However, there is still a long way to go before the lentiviral MMB technique might be 
considered for actual clinical application. Technical limitations, including the set up of 
strong magnetic fields capable to specifically focus on a desired site of exposure and reach 
deeper tissue regions, need to be overcome. Furthermore, more data concerning actual 
transgene expression over several months need to be provided to prove the actual long-
term efficiency of the method. And also off-target expression and related potential 
complications need to be addressed in more detail. 
Altogether, the here presented study provides a first fundament for the further optimization 
of the lentiviral MMB technique towards various possible applications in clinical gene 
therapy. 
 
 
 
4.5 Limitations of the study and outlook 
 
Lentiviral MMB were successfully applied in vivo to achieve local gene expression by 
combined magnetic and ultrasonic targeting. However, the study involved also certain 
technical limitations, which need to be considered for the accurate interpretation of the 
obtained results. 
 
The microvascular bed of the dorsal skin of mice, which was exposed by implantation of 
the DSFC, was the region of interest to which the lentiviral gene delivery was directed. 
This model was chosen due to several reasons: (1) the possibility to allow for long-term 
microscopic imaging of the vasculature in living animals, (2) its good accessibility from 
DISCUSSION | 86 
 
both sides during the transduction procedure and (3) its thin structure which allows for 
highest magnetic and ultrasonic penetrance. These factors make the DSFC an ideal model 
for the purpose to validate the method and conduct first experimental studies of certain 
molecules of interest. However, the actual tissue penetrance and applicability in deeper and 
larger vessels cannot be addressed by this model. To allow for effective gene transfer also 
in a deeper vascular network to treat for example hindlimb ischemia, a different magnet 
and ultrasound set up might be necessary. Furthermore, the DSFC model allows a follow 
up of gene expression only over 12-14 days as the resolution quality in the observation 
window decreases over time due to tissue remodelling and inflammatory processes. Also 
the welfare of mice cannot be guaranteed for a longer time period as the implanted 
chamber may cause skin lesions. For studies involving the assessment of gene expression 
over weeks to month another model has to be chosen. Interesting in this regard would be 
for example the non invasive targeting of the hindlimb vasculature also in view of later 
revascularization studies. 
 
In line with this latter point comes the problem of magnetically attracting lentiviral MMB 
also in vessels of deeper body regions, such as coronary arteries or limbs. The strength of a 
magnetic field, the so called magnetic flux density, strongly decreases with increasing 
distance to the magnet tip 
124
. While the magnetic attraction of lentiviral MMB to 
superficial vascular beds in vivo in principle should be no problem, deeper regions may be 
more complicated. First trials to circumvent this problem included the implantation of 
magnets 
125
 and magnetic field enhancing elements (FEE) 
126
 close to the intended site of 
gene transfer. Latter might be of particular interest for the treatment or prevention of stent 
restenosis, as such FEE can be designed in form of stents. The invasive implantation 
procedure may be easily performed in patients requiring a stent implantation anyway. The 
applicability is, however, very restricted to these patients with risk for stent restenosis. In a 
similar manner magnetisable orthopaedic implants could be used to specifically attract 
MNP-coupled genes or drugs to the sites of implantation resulting in improved 
engraftment. However, in general a more reasonable alternative to this invasive procedure 
can only be created by the technical advancements of magnetic fields by close 
interdisciplinary collaboration of physicists and biophysicians. 
 
Due to time limitations, the effects of modifications of the lentiviral vectors on gene 
targeting efficiency and circulation time have not been addressed in this study. Others 
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showed that the chemical coating of viral particles can yield so called shielding effects 
resulting in less interactions with antibodies and accordingly higher circulation times 
127, 
128
. In combination with the MMB technique it would be interesting to see if lentivirus 
shielding may result in a higher targeting efficiency or an altered off-target expression 
pattern. However, such surface modifications also require the careful re-evaluation of 
lentivirus-MMB complexation and in vitro performance, which will be object of future 
studies. Another interesting point would be to test if the unspecific expression observed in 
spleen and liver could be reduced using an endothelial specific promoter instead of the 
CMV promoter. We assume that the strong luciferase signal observed in the spleen rather 
results from resident immune cells than from endothelial cells. Endothelium specific 
promoters, such as the VE-cadherin promoter 
129
, could yield a higher specificity and 
reduce ectopic transgene expression thereby substantially reducing potential side effects. 
However, it has also been shown that transgene expression driven by tissue-specific 
promoters is oftentimes strongly reduced compared to the original viral promoters 
2
. 
Therefore, the actual pros and cons of such vector modifications need to be considered 
carefully. 
 
The effective and solid transgene expression of lentiviruses represents one of the major 
advantages of these vectors in experimental gene delivery. However, for most gene 
therapeutic applications only a temporary transgene expression is required. Over-
expression of VEGF, for example, may initially have beneficial effects for the 
revascularization and tissue regeneration in ischemic regions. However, long-term over-
expression of VEGF have been shown to result in myocardial failure and even tumour 
development 
130, 131
. To eliminate such risks, the use of lentiviral vectors with inducible 
transgene expression would be desirable. One promising approach in this regard is the Tet-
dependent expression system which is already widely applied as genetic tool in scientific 
research 
132, 133
. In combination with MMB-mediated gene targeting, such inducible gene 
expression vectors may have an enormous potential for clinical gene therapy enabling 
spatial as well as temporal control of gene expression. 
 
In terms of biocompatibility and safety of the lentiviral MMB technique further long-term 
studies need to be performed. The exact mechanism of excretion for the applied MNP has 
not been investigated in this study. Therefore, it is not clear if the MNP are eliminated by 
liver and kidney or if biotransformation resulted in complete uptake of the iron-oxide 
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components to the endogenous iron metabolism of the mice. Also the long-term profile of 
transgene expression has not been assessed so far. Expression in the dorsal skin as well as 
the other organs has been monitored 8 days after the transduction procedure. Although 
lentiviral expression is assumed to sustain over time due to stable genome integration it 
would be very interesting to see if the systemic expression profile changes over several 
month, especially in immunological active organs such as the spleen. Furthermore, the 
analysis of genome copy numbers integrated to the vasculature of the dorsal skin tissue 
could give more detailed information about the actual effectivity of the lentiviral MMB 
targeting approach and may help to improve the procedure. 
 
The therapeutic applicability of the lentiviral MMB technique was demonstrated by 
targeted delivery of VEGF and SHP-2 over-expression constructs ex vivo. By modulating 
the expression of both these proteins in the endothelium of isolated mouse aortas 
physiologically relevant effects could be detected. However, to completely verify the 
scientific and clinical potential of the MMB technique, in vivo experiments aiming at the 
modulation of therapeutically interesting molecules, such as the addressed VEGF or SHP-
2, need to be done. The DSFC model is well suited for these purposes as its microvascular 
bed offers microscopic access over several days. By this, angiogenesis-related studies can 
be excellently performed using the so called wound healing assay. Thereby, wound closure 
in the dorsal skin is monitored over several days by repeated injection of the fluorescent 
dye FITC-dextran allowing for visualization of the vascular network in the observation 
window of the DSFC. Also for the analysis of inflammatory processes, such as leukocyte 
adhesion and extravasation as well as vascular permeability, the DSFC model can be used. 
Furthermore, the use of transgenic animals in combination with the MMB technique may 
be highly interesting. For example, the observed anti-inflammatory properties of 
constitutively active SHP-2 E76A could be nicely verified in a diabetic mouse model, such 
as the established Lep
ob
 mouse strain. Furthermore, such a diabetic mouse model would be 
highly interesting in terms of gene therapeutic treatment of impaired diabetic wound 
healing, for example by targeted VEGF over-expression. 
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5 Summary 
 
In the clinical field of gene therapy, intravascularly applied targeting systems are promising 
advancements to improve specificity of a gene transfer. Magnetic microbubbles (MMB) 
combine the beneficial properties of magnetic nanoparticles (MNP) with those of ultrasound-
sensitive lipid microbubbles and have been shown to effectively bind different genetic 
vectors, including lentiviruses. The magnetic characteristics of these MMB are thereby 
determined by the choice of MNP embedded in the lipid shell. Furthermore, size, binding 
capacity and toxicity are decisive factors for the applicability and effectiveness of this gene 
delivery system. 
In this study, we characterized and compared different physico-chemical as well as biological 
properties of MMB coupled to silicon-oxide coated MNP (SO-Mag MMB) or 
polyethylenimine coated MNP (PEI-Mag MMB). While no differences between both MMB 
types were found concerning size, lentivirus binding, and toxicity, SO-Mag MMB exhibited 
superior characteristics regarding magnetic moment, magnetizability as well as transduction 
efficiency under static and flow conditions in vitro. 
By evaluating the contribution of the single technical parameter of the MMB technique we 
found MF exposure to be most critical under static conditions as well as under flow. Despite 
the observation that sole US exposure to lentiviral MMB did not enhance gene transfer to 
endothelial cells, we could demonstrate it to considerably contribute to the complete 
transduction efficiency of the whole MMB technique. 
By using lentiviral SO-Mag MMB, we achieved localized gene delivery to endothelial cells in 
an ex vivo perfusion model of murine aortas. Thus, we were able to utilize the new lentiviral 
SO-Mag MMB ex vivo to achieve site-directed over-expression of a lentiviral human VEGF 
construct resulting in actual VEGF secretion and induction of a proangiogenic phenotype in 
these vessels. 
With the same ex vivo model we were furthermore able to verify new compelling in vitro data 
concerning the role of the tyrosine phosphatase SHP-2 during vascular inflammation in 
insulin resistant endothelium. There, we could show that in untreated endothelial cells, SHP-2 
exhibits a basal phosphatase activity, which is lacking under insulin resistance conditions. The 
resulting hypothesis that SHP-2 phosphatase activity may negatively regulate endothelial 
inflammation was further supported by the finding that over-expression of a dominant 
negative SHP-2 mutant (CS) resulted in enhanced expression of the adhesion molecules 
ICAM-1 and VCAM-1 in insulin resistant endothelial cells. Accordingly, cells over-
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expressing a constitutively active SHP-2 mutant (E76A) showed a less inflammatory 
phenotype. Finally, we were able to confirm these findings ex vivo by using the lentiviral 
MMB technique to over-express the SHP-2 phosphatase mutants in the endothelial layer of 
isolated mouse aortas. In accordance with the in vitro data, ICAM-1 and VCAM-1 expression 
in these vessels was either enhanced or reduced under SHP-2 CS or E76A over-expression, 
respectively. These findings not only demonstrate SHP-2 to be a negative regulator of 
endothelial inflammation evolving under diabetic conditions, but also suggest SHP-2 as a new 
potential therapeutic target in this pathologic context. 
Lastly, we were able to prove the actual functionality of our MMB technique in vivo. After 
systemic injection of lentiviral SO-Mag MMB site-specific gene transfer was realized by local 
application of MF and US to the microvascular bed of the mouse dorsal skin. Interestingly, 
the contained MNP were nearly completely cleared from the body within four days indicating 
good compatibility of the method. In summary these achievements demonstrate that the 
lentiviral MMB technique as a valuable method for scientific applications and may be of 
substantial interest for future gene therapies. 
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7 Appendix 
 
7.1 Index of Abbreviations 
AAV Adeno-associated virus 
AB Antibody 
Ala Alanine 
ALD Adrenoleukodystrophy 
ANOVA Analysis of variance 
APC Allophycocyanin 
APS Ammoniumpersulfate 
AZ Aktenzeichen 
BCA Bicinchoninic acid 
BSA Bovine serum albumine 
cDNA Complementary DNA 
CMV Cytomegalovirus 
Ct Cycle of threshold 
Cys Cysteine 
CytoB Cytochalasin B 
DC Duty cycle 
ddH2O Double-distilled water 
Di Inner diameter 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Desoxiribonucleic acid 
Do Outer diameter 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DPPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine 
dsDNA Double-stranded DNA 
DSFC Dorsal skinfold chamber 
dsRed Discosoma sp. red fluorescent protein 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
env Envelope protein 
ET-1 Endothelin-1 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
Fe Iron 
FEE Field enhancing element 
FITC Fluorescein isothiocyanate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GFP Green fluorescent protein 
Glu Glutamine 
HBSS Hank’s buffered salt solution 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV-1 Human immunodeficiency virus-1 
HRP Horseradish peroxidase 
HUVEC Human umbilical cord vascular endothelial cells 
i.a. intra arterial 
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i.p. intra peritoneal 
i.v. intra venous 
ICAM-1 Intercellular adhesion molecule-1 
IgG Immunoglobulin G 
IP Infectious particles 
IRES-GFP Internal ribosome entry site-coupled green fluorescent protein 
IVC Individually ventilated cage 
Luc-MMB Luciferase lentivirus coated MMB 
LV Lentivirus 
MAPK Mitogen activated protein kinase 
mc Monoclonal 
MF Magnetic field 
MMB Magnetic microbubble 
MNP Magnetic nanoparticle 
MOI Multiplicity of infection 
MPS Magnetic particle spectroscopy 
mRNA Messenger ribonucleic acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MβCD Methyl-β-cyclodextrin 
NAD(P)H Nicotinamide adenine dinucleotide phosphate 
NO Nitric oxide 
o.a.d. Of applied dose 
OCT Optimal cutting temperature embedding medium 
PAI-1 Plasminogen activator inhibitor-1 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline with tween 
pDNA Plasmid DNA 
PECAM-1 Platelet endotheliala cell adhesion molecule-1 
PEG Polyethylene glycol 
PEI Polyethylenimine 
PEI-Mag Polyethylenimine-coated magnetic nanoparticles 
PFA Paraformadehyde 
pH negative of the logarithm to base 10 of the molar concentration of hydrogen ions 
PI3K Phosphoinositide-3 kinase 
pNPP Para-nitrophenylphosphate 
PTP Protein tyrosine phosphatase 
PtpI IV PTP inhibitor IV 
pY Phospho-tyrosine 
qRT-PCR Quantitative real time polymerase chain reaction 
RAS Rat sarcoma 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
S1 Safety level 1 
S2 Safety level 2 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
Ser Serine 
SH2 domain Src homology 2 domain 
SHP-2 Src homology 2 domain-containing protein tyrosine phosphatase-2 
SHP-2 CS Dominant negative phosphatase mutant of SHP-2 (Cys459 to Ser459) 
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SHP-2 E76A Constitutively active phosphatase mutant of SHP-2 (Glu76 to Ala76) 
SHP-2 WT Wild type form of SHP-2 (unmodified) 
siRNA Small interfering ribonucleic acid 
SO-Mag Silicon oxide-coated magnetic nanoparticles 
SPION Superparamagnetic iron-oxide nanoparticle 
ssDNA Single-stranded DNA 
ssRNA Single-stranded ribonucleic acid 
TBS-T Tris buffered saline with tween 
TEMED Tetramethylethylenediamine 
Tyr Tyrosine 
US Ultrasound 
VCAM-1 Vascular cell adhesion molecule-1 
VE-cadherin Vascular-endothelial cadherin 
veff-Luc Viral enhanced firefly luciferase 
VEGF Vascular endothelial growth factor 
VP Viral particles 
VSV-G Glycoprotein G of the vesicular stomatitis virus 
WAS Wiskott–Aldrich syndrome 
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